Zithromax discount card

For the health and safety of all, MidMichigan Urgent Care â Clare is implementing a new admissions process for zithromax discount card its patients seeking treatment. Upon arrival, zithromax discount card patients are asked to wait in their car and call the Urgent Care staff. Following a brief symptom screening, patients will then be give instruction on location for treatment.âWith the increased cases in buy antibiotics, we are making changes to keep our patients safe,â said Paul Berg, M.D., president, MidMichigan Physicians Group.

ÂBy identifying the patientâs symptoms over the phone we are better able to safely accommodate their needs and reduce the risk of potential exposure to others seeking treatment.âAfter the health screening, if zithromax discount card patients are found to have symptoms of respiratory illness, or need to be tested for buy antibiotics, they may be directed to the Ambulatory Testing Center located at 703 N. McEwan Street zithromax discount card. Those without respiratory symptoms will be directed to enter MidMichiganâs Clare Urgent Care at 700 West 5th Street.âWhile this change is minor, it reinforces our commitment to patient safety and keeping our patients at the center of all that we do,â concluded Dr.

Berg.In addition to treatment location and zithromax discount card entry screening, MidMichigan continues to follow other buy antibiotics prevention protocols at all of its facilities. These include visitor limitations, universal masking, additional cleaning and sanitizing measures, and modification of waiting rooms and reception areas to accommodate social distancing. Virtual care options for patient care needs, as zithromax discount card well as online community education opportunities, are also now available.MidMichigan Urgent Care â Clare is open Monday through Friday, 8 a.m.

To 7 p.m., and Saturday and Sundays zithromax discount card 8 a.m. To 3 p.m. Those with inquiries may call Urgent Care at (989) 386-9911.As a service to the community, MidMichigan Health hosts a buy antibiotics informational hotline with a reminder zithromax discount card of CDC guidelines and recommendations.

Staff is also available to help answer community questions Monday through Friday from 8 a.m. To 5 zithromax discount card p.m. The hotline can be reached toll-free at (800) 445-7356 or (989) 794-7600 zithromax discount card.

In addition, inquiries can be sent to MidMichigan Health via Facebook messenger at www.facebook.com/midmichigan. More information can also be found at www.midmichigan.org/buy antibiotics19.Those interested in zithromax discount card a current list of buy antibiotics testing site locations may visit www.michigan.gov/antibioticstest.Hart is pictured with her dog, Ace, who provided great comfort to her when she returned home after receiving cancer treatments.Donna Hart was feeling great. She had sold her farm just north of Alpena and was enjoying a simpler life with her boyfriend, a cat and her beloved dog, Ace.

She was shocked when rushing through a shower she felt a lump in her left breast zithromax discount card. It was a life-altering moment, and sheâs happy to be zithromax discount card around to share her story.âYou know,â Hart said, âI was very happy living an active life and doing my thing. But I have to admit, I was taking my health for granted.â At age 62, Hart had only ever had one mammogram and wasnât big on going to the doctor, a philosophy she was raised with.

Not having insurance didnât zithromax discount card help incentivize her about being proactive with her health. But when she discovered the lump in October 2019, everything changed.âThere is no history breast cancer in my family, but it scared zithromax discount card me,â she said. Hartâs boyfriend was traveling for work at the time and after a few days of worrying on her own, she got up the courage to reach out to Christy L.

Werth, D.O., zithromax discount card her primary care provider. ÂDr. Werth was zithromax discount card amazing,â said Hart.

ÂShe got me in for zithromax discount card a mammogram that same day. They did an ultrasound where there was a lot of measuring going on, so I knew that wasnât a great sign. Dr.

Eggleston came in shortly after that, and talked with me about the biopsy he would be doing. He was very kind.âRadiologist Ben Eggleston, M.D., identified four lumps with one in the lymph nodes. He performed the necessary biopsies, and Hart was scheduled for a mastectomy within two weeks.

To help her get through she was assigned to work with Bonnie Goff, R.N., B.S.N., C.N.-B.N., breast nurse navigator. ÂI was so grateful to have Bonnie helping me,â said Hart. ÂThere is great fear of the unknown with cancer.

She met with me and shared resources. She came to all appointments with me and encouraged me to take things one step at a time.âGoff also helped Hart connect with other community services including Friends Together and the Breast and Cervical Cancer Control Navigation Program at District Health Department No. 4 where she applied and qualified for insurance coverage.

ÂAt my job, insurance was not offered,â Hart said. ÂI always paid my bills first and put my other needs after. When I knew that my treatment would be paid for, I was able to focus on being strong and following doctorsâ orders without having to worry about treatment and keeping up with costs.

That was a big deal.âGeneral Surgeon Michael Paulsell, M.D., performed Hartâs mastectomy and axillary lymph node dissection. She was happy that he was thorough and left nothing to chance. From there, she met with William Hitzelberger, D.O., medical oncologist in the Alpena Cancer Center.

ÂI appreciated that Dr. Hitzelberger was straightforward. He didnât offer false promises and had a good, honest approach,â said Hart.

ÂHe said weâd do everything we could do, and we did.â Hart was relieved to be given a tour of the facility and learn about what would happen during her chemotherapy and radiation treatments. Knowing what to expect and learning where everything was proved to be very helpful in easing anxiety. ÂSome of the staff members are so young, but boy are they smart and professional and caring.

You could tell they were working careers not jobs. It impressed me every day, and we really got to know each other.âMario Lacerna, M.D., radiation oncologist, administered the radiation treatments, explaining and educating Hart along the way. She was encouraged to rest when needed and frequently referred to the Breast Treatment Handbook given to her by Goff to help answer questions when she wasnât at the Medical Center.

She kept her sense of humor and determination. She also tried her best to be a positive force for other patients going through similar situations. ÂYou do build relationships,â said Hart.

ÂI look at life differently now.ââDonna is a striking example of the many different specialties patients encounter during their treatment of breast cancer,â stated Goff. ÂAt MidMichigan Health, we offer a skilled health care team that cares for patients from the initial diagnosis of cancer through treatment and into survivorship. Additionally, we ensure that patients have the needed resources to help eliminate any barriers to their care.âHart completed treatments in June of 2020.

She said that, aside from masking, she felt just as comfortable and safe receiving treatment during the buy antibiotics -19 zithromax as she did prior. She is in the follow-up phase of her treatment now with regular blood work and bone density checks. She actually looks forward to appointments so she has a chance to see those she has become close with.

She eats a healthy diet and lives more in the moment. ÂAttitude makes a huge difference,â she said. ÂI try to stay happy and grateful.

The staff at MidMichigan Medical Center â Alpena has made that effort easier.âTo help breast cancer patients navigate through the many choices available and determine which treatment options are right for them, MidMichigan Medical Centers in Alma, Alpena, and Midland offer comprehensive, multidisciplinary Breast Health Programs. These programs are comprised of a team of dedicated physicians, nurses, breast nurse navigators like Goff and other health professionals dedicated to developing individualized treatment plans and assisting patients through every step of their treatment and recovery process. Those who would like more information about MidMichigan Healthâs Breast Programs may visit www.midmichigan.org/breast..

Zithromax for urinary tract

	Zithromax	Myambutol
Discount price	500mg 360 tablet $467.99	400mg 360 tablet $259.95
Buy with credit card	Online	No
Buy with visa	At walgreens	RX pharmacy
Buy with Paypal	No	No

Abemaciclib 215268 his comment is here Verzenio Eli zithromax for urinary tract Lilly Canada Inc. N/A 2019-04-08 2025-04-08 N/A 2027-04-08 acalabrutinib 214504 Calquence AstraZeneca Canada Inc. N/A 2019-08-23 2025-08-23 N/A 2027-08-23 aclidinium bromide 157598 zithromax for urinary tract Tudorza Genuair AstraZeneca Canada Inc.

Duaklir Genuair 2013-07-29 2019-07-29 N/A 2021-07-29 afatinib dimaleate 158730 Giotrif Boehringer Ingelheim (Canada) Ltd. N/A 2013-11-01 2019-11-01 N/A 2021-11-01 aflibercept 149321 Eylea Bayer Inc. N/A 2013-11-08 2019-11-08 N/A 2021-11-08 albiglutide 165145 Eperzan zithromax for urinary tract GlaxoSmithKline Inc.

N/A 2015-07-15 2021-07-15 N/A 2023-07-15 alectinib hydrochloride 189442 Alecensaro Hoffmann-La Roche Limited N/A 2016-09-29 2022-09-29 N/A 2024-09-29 alirocumab 183116 Praluent Sanofi-aventis Canada Inc. N/A 2016-04-11 2022-04-11 N/A 2024-04-11 alogliptin benzoate 158335 Nesina Takeda Canada Inc. KazanoOseni 2013-11-27 2019-11-27 N/A 2021-11-27 alpelisib 226941 Piqray Novartis Pharmaceuticals Canada zithromax for urinary tract Inc.

N/A 2020-03-11 2026-03-11 N/A 2028-03-11 amifampridine (supplied as amifampridine phosphate) 232685 Firdapse Kye Pharmaceuticals Inc. N/A 2020-07-31 2026-07-31 N/A 2028-07-31 anthrax immune globulin (human) 200446 Anthrasil Emergent BioSolutions Canada Inc. N/A 2017-11-06 2023-11-06 Yes 2026-05-06 antihemophilic zithromax for urinary tract factor (recombinant BDD), Fc fusion protein 163447 Eloctate Sanofi-Aventis Canada Inc.

N/A 2014-08-22 2020-08-22 Yes 2023-02-22 antihemophilic factor (recombinant), pegylated 189709 Adynovate Takeda Canada Inc. N/A 2016-11-17 2022-11-17 Yes 2025-05-17 antihemophilic factor (recombinant, B-domain deleted, pegylated) (also known as damoctocog alfa pegol) 210935 Jivi Bayer Inc. N/A 2018-10-18 2024-10-18 Yes 2027-04-18 antihemophilic factor (recombinant, B-domain deleted) (also known as simoctocog alfa) 169551 Nuwiq Octapharma Pharmazeutika Produktionsges.m.b.H N/A 2014-10-23 2020-10-23 Yes 2023-04-23 antihemophilic factor VIII zithromax for urinary tract (recombinant), singlechain (also known as lonoctocog alfa) 190891 Afstyla CSL Behring Canada Inc.

N/A 2016-12-12 2022-12-12 Yes 2025-06-12 anthrax antigen fiate 212387 Biothrax Emergent Biodefense Operations Lansing LLC N/A 2018-12-13 2024-12-13 N/A 2026-12-13 antihemophilic factor VIII (recombinant, B-domain truncated), PEGylated (turoctocog alfa pegol) 218531 Esperoct Novo Nordisk Canada Inc. N/A 2019-07-04 2025-07-04 Yes 2028-01-04 apalutamide 211942 Erleada Janssen Inc. N/A 2018-07-03 2024-07-03 zithromax for urinary tract N/A 2026-07-03 apremilast 169862 Otezla Amgen Canada Inc.

N/A 2014-11-12 2020-11-12 N/A 2022-11-12 asfotase alfa 179340 Strensiq Alexion Pharma International SÃ rl N/A 2015-08-14 2021-08-14 Yes 2024-02-14 asunaprevir 172617 Sunvepra Bristol-Myers Squibb Canada N/A 2016-03-09 2022-03-09 N/A 2024-03-09 atezolizumab 196843 Tecentriq Hoffmann-La Roche Limited N/A 2017-04-12 2023-04-12 N/A 2025-04-12 avelumab 204052 Bavencio EMD Serono, a Division of EMD Inc., Canada N/A 2017-12-18 2023-12-18 N/A 2025-12-18 axicabtagene ciloleucel 218389 Yescarta Gilead Sciences Canada Inc N/A 2019-02-13 2025-02-13 N/A 2027-02-13 azelastine hydrochloride 169604 Dymista Meda Pharmaceuticals Ltd. N/A 2014-10-23 2020-10-23 Yes 2023-04-23 baloxavir marboxil 227361 Xofluza Hoffmann-La Roche Limited N/A 2020-02-19 2026-02-19 Yes 2028-08-19 baricitinib 193687 Olumiant Eli Lilly Canada Inc. N/A 2018-08-17 2024-08-17 N/A zithromax for urinary tract 2026-08-17 bazedoxifene acetate 160681 Duavive Pfizer Canada Inc.

N/A 2014-10-23 2020-10-23 N/A 2022-10-23 benralizumab 204008 Fasenra AstraZeneca Canada Inc. N/A 2018-02-22 2024-02-22 Yes 2026-08-22 bepotastine besilate 179294 Bepreve Bausch and Lomb Incorporated N/A 2016-07-27 2022-07-27 Yes 2025-01-27 bictegravir 203718 Biktarvy Gilead Sciences Canada, Inc. N/A 2018-07-10 2024-07-10 Yes 2027-01-10 bilastine 184231 Blexten Aralez Pharmaceutials Canada Inc zithromax for urinary tract .

N/A 2016-04-21 2022-04-21 Yes 2024-10-21 binimetinib 237410 Mektovi Pfizer Canada ULC N/A 2021-03-02 2027-03-02 N/A 2029-03-02 blinatumomab 181723 Blincyto Amgen Canada Incorporated N/A 2015-12-22 2021-12-22 Yes 2024-06-22 bosutinib 152211 Bosulif Pfizer Canada Inc. N/A 2014-03-07 2020-03-07 N/A 2022-03-07 botulism antitoxin heptavalen C/ D/ F/ G - zithromax for urinary tract (equine) 190645 Bat Emergent BioSolutions Inc. N/A 2016-12-08 2022-12-08 Yes 2025-06-08 brexpiprazole 192684 Rexulti Otsuka Pharmaceutical Co.

Ltd. N/A 2017-02-16 2023-02-16 Yes 2025-08-16 brexucabtagene autoleucel 246355 Tecartus Gilead Sciences Canada, zithromax for urinary tract Inc. N/A 2021-06-08 2027-06-08 N/A 2029-06-08 brigatinib 210369 Alunbrig Takeda Canada Incorporated N/A 2018-07-26 2024-07-26 N/A 2026-07-26 brivaracetam 183355 Brivlera UCB Canada Incorporated N/A 2016-03-09 2022-03-09 Yes 2024-09-09 brodalumab 195317 Siliq Bausch Health, Canada Inc.

N/A 2018-03-06 2024-03-06 N/A 2026-03-06 brolucizumab 226224 Beovu Novartis Pharmaceuticals Canada Inc. N/A 2020-03-12 2026-03-12 N/A 2028-03-12 bromfenac sodium zithromax for urinary tract sesquihydrate 171657 Prolensa Bausch &. Lomb Incorporated N/A 2015-03-26 2021-03-26 N/A 2023-03-26 burosumab 216239 Crysvita Kyowa Kirin Limited N/A 2018-12-05 2024-12-05 Yes 2027-06-05 cabotegravir sodium 227315 Vocabria ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabotegravir 227315 Cabenuva ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabozantinib (supplied as cabozantinib (S)-malate) 206230 Cabometyx Ipsen Biopharmaceuticals Canada Inc.

N/A 2018-09-14 2024-09-14 N/A 2026-09-14 calcifediol 205392 Rayaldee Vifor Fresenius Medical Care Renal Pharma Ltd N/A 2018-07-10 2024-07-10 N/A 2026-07-10 canagliflozin 157505 Invokana Janssen Inc. InvokametInvokamet XR 2014-05-23 2020-05-23 N/A zithromax for urinary tract 2022-05-23 caplacizumab 230001 Cablivi Sanofi-Aventis Canada Inc. N/A 2020-02-28 2026-02-28 N/A 2028-02-28 carfilzomib 184479 Kyprolis Amgen Canada Inc.

N/A 2016-01-15 2022-01-15 N/A 2024-01-15 carglumic acid 171358 Carbaglu Recordati Rare Diseases N/A 2015-04-10 2021-04-10 Yes 2023-10-10 cedazuridine 234610 Inqovi Otsuka Pharmaceutical Co., Ltd. N/A 2020-07-07 zithromax for urinary tract 2026-07-07 N/A 2028-07-07 ceftolozane 178006 Zerbaxa Merck Canada Inc. N/A 2015-09-30 2021-09-30 N/A 2023-09-30 cemiplimab 218718 Libtayo Sanofi-Aventis Canada Inc.

N/A 2019-04-10 2025-04-10 N/A 2027-04-10 cenegermin 218145 Oxervate DompÃ© farmaceutici S.p.A. N/A 2019-02-08 2025-02-08 N/A 2027-02-08 ceritinib 175702 Zykadia Novartis Pharmaceuticals zithromax for urinary tract Canada Inc. N/A 2015-03-27 2021-03-27 N/A 2023-03-27 cerliponase alfa 216539 Brineura Biomarin International Limited N/A 2018-12-19 2024-12-19 Yes 2027-06-19 coagulation factor IX (recombinant), albumin fusion protein (rIX-FP) 180793 Idelvion CSL Behring Canada Inc.

N/A 2016-01-26 2022-01-26 Yes 2024-07-26 coagulation factor IX (recombinant), pegylated (nonacog beta pegol) 201114 Rebinyn Novo Nordisk Canada Inc. N/A 2017-11-29 2023-11-29 Yes 2026-05-29 coagulation factor IX, Fc fusion protein 163614 Alprolix Sanofi-Aventis Canada zithromax for urinary tract Inc. N/A 2014-03-20 2020-03-20 Yes 2022-09-20 cobimetinib 182788 Cotellic Hoffmann-La Roche Limited N/A 2016-02-22 2022-02-22 N/A 2024-02-22 crisaborole 206906 Eucrisa Pfizer Canada Inc.

N/A 2018-06-07 2024-06-07 Yes 2026-12-07 cysteamine bitartrate 191347 Procysbi Horizon Pharma Ireland Ltd. N/A 2017-06-13 2023-06-13 Yes 2025-12-13 zithromax for urinary tract dabrafenib mesylate 157590 Tafinlar Novartis Pharmaceuticals Canada Inc. N/A 2013-07-16 2019-07-16 N/A 2021-07-16 daclatasvir 172616 Daklinza Bristol-Myers Squibb Canada N/A 2015-08-13 2021-08-13 N/A 2023-08-13 daclizumab beta 190458 Zinbryta Biogen Canada Inc.

N/A 2016-12-08 2022-12-08 N/A 2024-12-08 dacomitinib 214572 Vizimpro Pfizer Canada zithromax for urinary tract Inc. N/A 2019-02-26 2025-02-26 N/A 2027-02-26 dalbavancin (supplied as dalbavancin hydrochloride) 212390 Xydalba Cipher Pharmaceuticals Inc. N/A 2018-09-04 2024-09-04 N/A 2026-09-04 dapagliflozin propanediol 160877 Forxiga AstraZeneca Canada Inc.

XigduoQtern 2014-12-12 zithromax for urinary tract 2020-12-12 N/A 2022-12-12 daratumumab 187648 Darzalex Janssen Inc. Darzalex SC 2016-06-29 2022-06-29 N/A 2024-06-29 darolutamide 226146 Nubeqa Bayer Inc. N/A 2020-02-20 2026-02-20 N/A 2028-02-20 deferiprone 162924 Ferriprox Chiesi Canada Corp.

N/A 2015-02-13 2021-02-13 Yes 2023-08-13 defibrotide sodium 200808 zithromax for urinary tract Defitelio Jazz Pharmaceuticals Ireland Limited N/A 2017-07-10 2023-07-10 Yes 2026-01-10 difluprednate 154517 Durezol Novartis Pharmaceuticals Canada Inc. N/A 2013-11-04 2019-11-04 Yes 2022-05-04 dimethyl fumarate 154776 Tecfidera Biogen Idec Canada Inc. N/A 2013-04-03 2019-04-03 Yes 2021-10-03 dinutuximab 212066 Unituxin United Therapeutics Corporation N/A 2018-11-28 2024-11-28 Yes 2027-05-28 dolutegravir sodium 161084 Tivicay ViiV Healthcare ULC TriumeqJulucaDovato 2013-10-31 2019-10-31 Yes 2022-05-01 doravirine 211293 Pifeo Merck Canada Inc.

Delstrigo 2018-10-12 2024-10-12 N/A 2026-10-12 dulaglutide 168671 Trulicity zithromax for urinary tract Eli Lilly Canada Inc. N/A 2015-11-10 2021-11-10 N/A 2023-11-10 dupilumab 201285 Dupixent Sanofi-Aventis Canada Inc. N/A 2017-11-30 2023-11-30 Yes 2026-05-30 durvalumab 202953 Imfinzi AstraZeneca Canada Inc.

N/A 2017-11-03 2023-11-03 N/A 2025-11-03 edaravone 214391 Radicava Mitsubishi zithromax for urinary tract Tanabe Pharma Corporation N/A 2018-10-03 2024-10-03 N/A 2026-10-03 edoxaban 187363 Lixiana Servier Canada Inc. N/A 2016-11-04 2022-11-04 N/A 2024-11-04 efinaconazole 159416 Jublia Bausch Health, Canada Inc. N/A 2013-10-02 2019-10-02 N/A 2021-10-02 elagolix 209513 Orilissa AbbVie Corporation N/A 2018-10-05 2024-10-05 N/A 2026-10-05 elexacaftor 246955 Trikafta Vertex Pharmaceuticals (Canada) Incorporated N/A 2021-06-18 2027-06-18 Yes 2029-12-18 eliglustat tartrate 183050 Cerdelga Genzyme Canada, A division of Sanofi-aventis Canada Inc.

N/A 2017-04-21 2023-04-21 N/A 2025-04-21 elosulfase alfa 170340 Vimizim Biomarin zithromax for urinary tract International Limited N/A 2014-07-02 2020-07-02 Yes 2023-01-02 elotuzumab 188144 Empliciti Bristol-Myers Squibb Canada N/A 2016-06-21 2022-06-21 N/A 2024-06-21 eluxadoline 190162 Viberzi Allergan inc. N/A 2017-01-26 2023-01-26 N/A 2025-01-26 emicizumab 212635 Hemlibra Hoffmann-La Roche Limited N/A 2018-08-02 2024-08-02 Yes 2027-02-02 empagliflozin 162552 Jardiance Boehringer Ingelheim (Canada) Ltd. SynjardyGlyxambi 2015-07-23 2021-07-23 N/A 2023-07-23 enasidenib mesylate 217033 Idhifa Celgene Inc.

N/A 2019-02-06 2025-02-06 N/A 2027-02-06 encorafenib 237413 Braftovi Pfizer Canada ULC N/A 2021-03-02 2027-03-02 N/A 2029-03-02 entrectinib 227517 Rozlytrek Hoffmann-La Roche Limited N/A 2020-02-10 2026-02-10 Yes 2028-08-10 zithromax for urinary tract eptinezumab 233288 Vyepti Lundbeck Canada Inc. N/A 2021-01-11 2027-01-11 N/A 2029-01-11 erdafitinib 224529 Balversa Janssen Inc. N/A 2019-10-25 2025-10-25 N/A 2027-10-25 erenumab 208607 Aimovig Novartis Pharmaceuticals Canada Inc.

N/A 2018-08-01 2024-08-01 N/A zithromax for urinary tract 2026-08-01 ertugliflozin 204724 Steglatro Merck Canada Inc. SteglujanSegluromet 2018-05-09 2024-05-09 N/A 2026-05-09 eslicarbazepine acetate 165665 Aptiom Sunovion Pharmaceuticals Canada Inc. N/A 2014-07-08 2020-07-08 Yes 2023-01-08 estetrol monohydrate 236197 zithromax for urinary tract Nextstellis Searchlight Pharma Inc.

N/A 2021-03-05 2027-03-05 N/A 2029-03-05 evolocumab 178234 Repatha Amgen Canada Inc. N/A 2015-09-10 2021-09-10 Yes 2024-03-10 fedratinib (supplied as fedratinib hydrochloride) 229866 Inrebic Celgene Inc. N/A 2020-07-27 2026-07-27 N/A 2028-07-27 ferric pyrophosphate citrate 239850 Triferic Avnu Rockwell zithromax for urinary tract Medical Inc.

N/A 2021-04-22 2027-04-22 Yes 2029-10-22 finafloxacin 172450 Xtoro MerLion Pharmaceuticals GmbH N/A 2016-03-11 2022-03-11 Yes 2024-09-11 flibanserin 189352 Addyi Searchlight Pharma Inc. N/A 2018-02-27 2024-02-27 N/A 2026-02-27 florbetaben (18F) 193105 Neuraceq Isologic Innovative Radiopharmaceuticals Ltd. N/A 2017-02-22 2023-02-22 N/A 2025-02-22 follitropin delta 188743 Rekovelle Ferring zithromax for urinary tract Inc.

N/A 2018-03-22 2024-03-22 N/A 2026-03-22 fostamatinib (supplied as fostamatinib disodium) 232078 Tavalisse Rigel Pharmaceuticals Inc. N/A 2020-11-19 2026-11-19 N/A 2028-11-19 fremanezumab 226828 Ajovy Teva Canada Limited N/A 2020-04-09 2026-04-09 N/A 2028-04-09 gadoterate meglumine 186333 Dotarem Guerbet N/A 2016-11-26 2022-11-26 Yes 2025-05-26 galcanezumab 219521 Emgality Eli Lilly Canada Inc. N/A 2019-07-30 2025-07-30 N/A 2027-07-30 galsulfase 159020 Naglazyme BioMarin zithromax for urinary tract Pharmaceutical Inc.

N/A 2013-09-16 2019-09-16 Yes 2022-03-16 gemtuzumab ozogamicin 223091 Mylotarg Pfizer Canada ULC N/A 2019-11-28 2025-11-28 Yes 2028-05-28 gilteritinib fumarate 227918 Xospata Astellas Pharma Canada Inc. N/A 2019-12-23 2025-12-23 N/A 2027-12-23 givosiran (supplied as givosiran sodium) 237194 Givlaari Alnylam Netherlands B.V.. N/A 2020-10-09 2026-10-09 N/A 2028-10-09 glasdegib 225793 Daurismo Pfizer Canada ULC N/A 2020-04-28 2026-04-28 N/A 2028-04-28 glecaprevir, zithromax for urinary tract pibrentasvir 202233 Maviret AbbVie Corporation N/A 2017-08-16 2023-08-16 Yes 2026-02-16 glycerol phenylbutyrate 174219 Ravicti Horizon Pharma Ireland Ltd.

N/A 2016-03-18 2022-03-18 Yes 2024-09-18 grazoprevir, elbasvir 185866 Zepatier Merck Canada Inc. N/A 2016-01-19 2022-01-19 N/A 2024-01-19 guanfacine hydrochloride 150741 Intuniv XR Takeda Canada Inc. N/A 2013-07-05 2019-07-05 Yes zithromax for urinary tract 2022-01-05 guselkumab 200590 Tremfya Janssen Inc.

N/A 2017-11-10 2023-11-10 N/A 2025-11-10 haemagglutinin strain A (H5N1) 115398 Arepanrix H5N1 ID Biomedical Corporation of Quebec N/A 2013-02-13 2019-02-13 Yes 2021-08-13 hemin 212276 Panhematin Recordati Rare Diseases Canada Inc. N/A 2018-07-13 2024-07-13 N/A 2026-07-13 ibrutinib 174029 Imbruvica Janssen Inc. N/A 2014-11-17 2020-11-17 Yes 2023-05-17 icatibant acetate 162918 Firazyr Takeda Canada zithromax for urinary tract Inc.

N/A 2014-06-04 2020-06-04 Yes 2022-12-04 icosapent ethyl 227235 Vascepa HLS Therapeutics Inc. N/A 2019-12-30 2025-12-30 N/A 2027-12-30 idarucizumab 182503 Praxbind Boehringer Ingelheim (Canada) Ltd N/A 2016-04-29 2022-04-29 N/A 2024-04-29 idecabtagene vicleucel 244266 Abecma Celgene Inc. N/A 2021-05-26 2027-05-26 zithromax for urinary tract N/A 2029-05-26 idelalisib 172652 Zydelig Gilead Sciences Canada Inc.

N/A 2015-03-27 2021-03-27 N/A 2023-03-27 inotersen sodium 214274 Tegsedi Akcea Therapeutics Inc. N/A 2018-10-03 2024-10-03 N/A 2026-10-03 inotuzumab ozogamicin 204077 zithromax for urinary tract Besponsa Pfizer Canada Inc. N/A 2018-03-15 2024-03-15 N/A 2026-03-15 insulin degludec 198124 Tresiba Novo Nordisk Canada Inc.

Xultophy 2017-08-25 2023-08-25 Yes 2026-02-25 ioflupane (123I) 201481 Datscan GE Healthcare Canada Inc. N/A 2017-12-07 zithromax for urinary tract 2023-12-07 N/A 2025-12-07 iron isomaltoside 1000 193890 Monoferric Pharmacosmos A/S N/A 2018-06-22 2024-06-22 N/A 2026-06-22 isatuximab 229245 Sarclisa Sanofi-Aventis Canada Inc. N/A 2020-04-29 2026-04-29 N/A 2028-04-29 isavuconazole (supplied as isavuconazonium sulfate) 208919 Cresemba Avir Pharma Inc.

N/A 2018-12-19 2024-12-19 N/A 2026-12-19 ivabradine hydrochloride 166949 Lancora Servier Canada Inc. N/A 2016-12-23 2022-12-23 Yes 2025-06-23 zithromax for urinary tract ivermectin 172733 Rosiver Galderma Canada Inc. N/A 2015-04-22 2021-04-22 N/A 2023-04-22 ixazomib (supplied as ixazomib citrate) 190498 Ninlaro Takeda Canada Inc.

N/A 2016-08-04 2022-08-04 N/A 2024-08-04 ixekizumab 184993 Taltz Eli Lilly Canada Inc. N/A 2016-05-25 zithromax for urinary tract 2022-05-25 Yes 2024-11-25 lanadelumab 213920 Takhzyro Takeda Canada Inc. N/A 2018-09-19 2024-09-19 Yes 2027-03-19 larotrectinib (supplied as larotrectinib sulfate) 219998 Vitrakvi Bayer Inc.

N/A 2019-07-10 2025-07-10 Yes 2028-01-10 latanoprostene bunod 211732 Vyzulta Bausch &. Lomb Incorporated N/A 2018-12-27 2024-12-27 N/A 2026-12-27 ledipasvir 173180 Harvoni Gilead Sciences Canada Inc zithromax for urinary tract . N/A 2014-10-15 2020-10-15 Yes 2023-04-15 lefamulin acetate 233292 Xenleta Sunovion Pharmaceuticals Canada Inc.

N/A 2020-07-10 2026-07-10 N/A 2028-07-10 lemborexant 231286 Dayvigo Eisai Limited N/A 2020-11-04 2026-11-04 N/A 2028-11-04 lenvatinib mesylate 180877 Lenvima Eisai Limited N/A 2015-12-22 2021-12-22 N/A 2023-12-22 letermovir 204165 Prevymis Merck Canada Inc. N/A 2017-11-01 2023-11-01 zithromax for urinary tract N/A 2025-11-01 levomilnacipran hydrochloride 167319 Fetzima Allergan Inc. N/A 2015-05-08 2021-05-08 N/A 2023-05-08 lifitegrast 199810 Xiidra Novartis Pharmaceuticals Canada Inc.

N/A 2017-12-22 2023-12-22 N/A 2025-12-22 linaclotide 161056 Constella Forest Laboratories Canada Inc. N/A 2013-12-02 2019-12-02 N/A 2021-12-02 lixisenatide 193862 Adlyxine zithromax for urinary tract Sanofi-aventis Canada Inc. Soliqua 2017-05-25 2023-05-25 N/A 2025-05-25 lomitapide mesylate 160385 Juxtapid Aegerion Pharmaceuticals Canada Ltd.

N/A 2014-02-04 2020-02-04 N/A 2022-02-04 lorlatinib 215733 Lorbrena Pfizer Canada ULC N/A 2019-02-22 2025-02-22 N/A 2027-02-22 lubiprostone 179333 Amitiza Sucampo Pharma Americas LLC N/A 2015-10-14 2021-10-14 N/A 2023-10-14 lumacaftor 181715 Orkambi Vertex Pharmaceuticals (Canada) Incorporated N/A 2016-01-26 2022-01-26 Yes 2024-07-26 luspatercept 236441 Reblozyl Celgene Inc. N/A 2020-09-25 2026-09-25 N/A 2028-09-25 lutetium177 Lu zithromax for urinary tract oxodotreotide 217184 Lutathera Advanced Accelerator Applications USA, Inc. N/A 2019-01-09 2025-01-09 N/A 2027-01-09 macitentan 161372 Opsumit Janssen Inc.

N/A 2013-11-06 2019-11-06 Yes 2022-05-06 mecasermin 235023 Increlex Ipsen Biopharmaceuticals Canada zithromax for urinary tract Inc. N/A 2020-12-17 2026-12-17 Yes 2029-06-17 mepolizumab 179850 Nucala GlaxoSmithKline Inc. N/A 2015-12-03 2021-12-03 Yes 2024-06-03 midostaurin 201101 Rydapt Novartis Pharmaceuticals Canada Inc.

N/A 2017-07-21 2023-07-21 Yes 2026-01-21 mifepristone 160063 Mifegymiso Linepharma International Limited N/A 2015-07-29 2021-07-29 Yes 2024-01-29 migalastat hydrochloride 196956 Galafold Amicus Therapeutics UK LTD N/A 2017-09-05 2023-09-05 N/A zithromax for urinary tract 2025-09-05 modified vaccinia zithromax (ankara-bavarian nordic) 144762 Imvamune Bavarian Nordic A/S N/A 2013-11-21 2019-11-21 N/A 2021-11-21 naloxegol oxalate 167790 Movantik Knight Therapeutics Inc. N/A 2015-06-02 2021-06-02 N/A 2023-06-02 necitumumab 193689 Portrazza Eli Lilly Canada Inc. N/A 2017-03-16 2023-03-16 N/A 2025-03-16 neisseria meningitidis serogroup A polysaccharide, neisseria meningitidis serogroup C polysaccharide, neisseria meningitidis serogroup W-135 polysaccharide, neisseria meningitidis serogroup Y polysaccharide, conjugated to tetanus toxoid carrier protein 154290 Nimenrix Pfizer Canada Inc.

N/A 2013-03-05 2019-03-05 Yes 2021-09-05 neisseria meningitidis serogroup B recombinant lipoprotein 2086 (rLP2086) subfamily A and Neisseria meningitidis serogroup B recombinant lipoprotein 2086 zithromax for urinary tract (rLP2086) subfamily B 195550 Trumenba Pfizer Canada Inc. N/A 2017-10-05 2023-10-05 Yes 2026-04-05 neratinib maleate 218224 Nerlynx Knight Therapeutics Inc. N/A 2019-07-16 2025-07-16 N/A 2027-07-16 netupitant 196495 Akynzeo Elvium Life Sciences N/A 2017-09-28 2023-09-28 N/A 2025-09-28 nintedanib (supplied as nintedanib esilate) 176043 Ofev Boehringer Ingelheim (Canada) Ltd N/A 2015-06-25 2021-06-25 N/A 2023-06-25 niraparib 216792 Zejula GlaxoSmithKline Inc.

N/A 2019-06-27 2025-06-27 N/A 2027-06-27 nivolumab 180828 Opdivo Bristol-Myers-Squibb Canada N/A 2015-09-25 2021-09-25 Yes 2024-03-25 nusinersen 200070 Spinraza Biogen Canada Inc zithromax for urinary tract . N/A 2017-06-29 2023-06-29 Yes 2025-12-29 obeticholic acid 198418 Ocaliva Intercept Pharmaceuticals Inc. N/A 2017-05-24 2023-05-24 N/A 2025-05-24 obiltoxaximab 230825 Anthim Elusys Therapeutics, Inc.

N/A 2020-07-30 2026-07-30 N/A 2028-07-30 obinutuzumab 168227 Gazyva Hoffmann-La Roche Limited N/A 2014-11-25 2020-11-25 N/A 2022-11-25 ocrelizumab 198094 Ocrevus Hoffmann-La Roche Limited N/A 2017-08-14 2023-08-14 N/A 2025-08-14 ocriplasmin 161356 zithromax for urinary tract Jetrea ThromboGenics N.V. N/A 2013-08-13 2019-08-13 N/A 2021-08-13 olaparib 182823 Lynparza AstraZeneca Canada Inc. N/A 2016-04-29 2022-04-29 N/A 2024-04-29 olaratumab 203478 Lartruvo Eli Lilly Canada Inc.

N/A 2017-11-23 2023-11-23 N/A 2025-11-23 ombitasvir, paritaprevir, dasabuvir sodium 174739 Holkira zithromax for urinary tract Pak Abbvie Corporation Technivie 2014-12-22 2020-12-22 N/A 2022-12-22 onasemnogene abeparvovec 239719 Zolgensma Novartis Pharmaceuticals Canada Inc. N/A 2020-12-15 2026-12-15 Yes 2029-06-15 osimertinib mesylate 188171 Tagrisso AstraZeneca Canada Inc. N/A 2016-07-05 2022-07-05 N/A 2024-07-05 ozanimod (supplied as ozanimod hydrochloride) 232761 Zeposia Celgene Inc.

N/A 2020-10-02 2026-10-02 N/A 2028-10-02 ozenoxacin 192925 Ozanex Ferrer zithromax for urinary tract Internacional, S.A. N/A 2017-05-01 2023-05-01 Yes 2025-11-01 palbociclib 182048 Ibrance Pfizer Canada Inc. N/A 2016-03-16 2022-03-16 N/A 2024-03-16 pasireotide diaspartate 145005 Signifor Novartis Pharmaceuticals Canada Inc.

Signifor Lar 2013-09-23 2019-09-23 N/A 2021-09-23 patiromer sorbitex calcium 210368 zithromax for urinary tract Veltassa Vifor Fresenius Medical Care Renal Pharma Ltd. N/A 2018-10-03 2024-10-03 N/A 2026-10-03 patisiran (as patisiran sodium) 221896 Onpattro Alnylam Netherlands B.V. N/A 2019-06-07 zithromax for urinary tract 2025-06-07 N/A 2027-06-07 peginterferon beta-1a 166974 Plegridy Biogen Idec Canada Inc.

N/A 2015-08-10 2021-08-10 N/A 2023-08-10 pembrolizumab 175884 Keytruda Merck Canada Inc. N/A 2015-05-19 2021-05-19 Yes 2023-11-19 peramivir 191280 Rapivab BioCryst Pharmaceuticals Inc. N/A 2017-01-05 2023-01-05 N/A 2025-01-05 perampanel 153747 Fycompa Eisai Limited N/A 2013-04-04 2019-04-04 Yes 2021-10-04 pitolisant zithromax for urinary tract hydrochloride 238175 Wakik Endo Ventures Ltd.

N/A 2021-05-25 2027-05-25 N/A 2029-05-25 plecanatide 215288 Trulance Bausch Health, Canada Inc. N/A 2019-10-10 2025-10-10 N/A 2027-10-10 polatuzumab vedotin 232303 Polivy Hoffmann-La Roche Limited N/A 2020-07-09 2026-07-09 N/A 2028-07-09 polidocanol 177359 Varithena Provensis Ltd. N/A 2015-08-04 2021-08-04 N/A 2023-08-04 pomalidomide 165891 Pomalyst Celgene Inc zithromax for urinary tract .

N/A 2014-01-20 2020-01-20 Yes 2022-07-20 pralatrexate 207545 Folotyn Servier Canada Inc. N/A 2018-10-26 2024-10-26 N/A 2026-10-26 pralsetinib 243731 Gavreto Hoffmann-La Roche Limited N/A 2021-06-30 2027-06-30 N/A 2029-06-30 prasterone 198822 Intrarosa Endoceutics Inc. N/A 2019-11-01 2025-11-01 N/A 2027-11-01 ponatinib zithromax for urinary tract hydrochloride 165121 Iclusig Ariad Pharmaceuticals Inc.

N/A 2015-04-02 2021-04-02 N/A 2023-04-02 ponesimod 239537 Ponvory Janssen Inc. N/A 2021-04-28 2027-04-28 N/A 2029-04-28 propiverine hydrochloride 188323 Mictoryl / Mictoryl Pediatric Duchesnay Inc. N/A 2017-01-05 2023-01-05 Yes 2025-07-05 radium - zithromax for urinary tract 223 dichloride 161312 Xofigo Bayer Inc.

N/A 2013-12-12 2019-12-12 N/A 2021-12-12 ramucirumab 176810 Cyramza Eli Lilly Canada Inc. N/A 2015-07-16 2021-07-16 N/A 2023-07-16 ravulizumab 217955 Ultomiris Alexion Pharma GmbH N/A 2019-08-28 2025-08-28 N/A 2027-08-28 recombinant haemagglutinin protein-strain A (H1N1) recombinant haemagglutinin protein-strain A (H3N2) recombinant haemagglutinin protein-strain B (Victoria) recombinant haemagglutinin protein-strain B (Yamagata) 235672 Supemtek Sanofi Pasteur Limited N/A 2021-01-14 2027-01-14 N/A 2029-01-14 recombinant human papillomazithromax types 31, 33, 45, 52 and 58 170006 Gardasil 9 Merck Canada Inc. N/A 2015-02-05 2021-02-05 Yes 2023-08-05 recombinant neisseria meningitidis group B NHBA fusion protein, recombinant neisseria meningitidis group zithromax for urinary tract B NadA protein, recombinant neisseria meningitidis group B FHBP fusion protein, outer membrane vesicle (neisseria meningitidis group B NZ98/254 strain) 147275 Bexsero GlaxoSmithKline Inc.

N/A 2013-12-06 2019-12-06 Yes 2022-06-06 recombinant porcine factor VIII (antihemophilic factor (recombinant), porcine sequence) 177290 Obizur Takeda Canada Inc. N/A 2015-10-14 2021-10-14 N/A 2023-10-14 regorafenib monohydrate 157970 Stivarga Bayer Inc. N/A 2013-03-11 2019-03-11 Yes 2021-09-11 remdesivir 240551 Veklury Gilead Sciences zithromax for urinary tract Canada, Inc.

N/A 2020-07-27 2026-07-27 N/A 2028-07-27 reslizumab 185873 Cinqair Teva Canada Limited N/A 2016-07-20 2022-07-20 Yes 2025-01-20 ribociclib (supplied as ribociclib succinate) 203884 Kisqali Novartis Pharmaceuticals Canada Inc. N/A 2018-03-02 2024-03-02 N/A 2026-03-02 rifaximin 161256 Zaxine Salix Pharmaceuticals Inc. N/A 2013-08-13 2019-08-13 N/A 2021-08-13 riociguat 162761 zithromax for urinary tract Adempas Bayer Inc.

N/A 2013-09-19 2019-09-19 N/A 2021-09-19 ripretinib 234688 Qinlock Deciphera Pharmaceuticals, LLC N/A 2020-06-19 2026-06-19 N/A 2028-06-19 risankizumab 215753 Skyrizi AbbVie Corporation N/A 2019-04-17 2025-04-17 N/A 2027-04-17 risdiplam 242373 Evrysdi Hoffman-La Roche Limited N/A 2021-04-14 2027-04-14 Yes 2029-10-14 romidepsin 152293 Istodax Celgene Inc. N/A 2013-10-16 2019-10-16 N/A 2021-10-16 romosozumab 197713 Evenity Amgen zithromax for urinary tract Canada Inc. N/A 2019-06-17 2025-06-17 N/A 2027-06-17 rupatadine (supplied as rupatadine fumarate) 186488 Rupall Medexus Pharmaceuticals Inc.

N/A 2016-07-20 2022-07-20 Yes 2025-01-20 sacubitril 182734 Entresto Novartis Pharmaceuticals Canada Inc. N/A 2015-10-02 2021-10-02 N/A 2023-10-02 safinamide (as safinamide mesylate) 207115 zithromax for urinary tract Onstryv Valeo Pharma Inc. N/A 2019-01-10 2025-01-10 N/A 2027-01-10 sarilumab 191745 Kevzara Sanofi-aventis Canada Inc.

N/A 2017-01-12 2023-01-12 N/A 2025-01-12 satralizumab 233642 Enspryng Hoffmann-La Roche Limited N/A 2020-06-01 2026-06-01 Yes 2028-12-01 sebelipase alfa 204085 Kanuma Alexion Pharma GmbH N/A 2017-12-15 2023-12-15 Yes 2026-06-15 secukinumab 170732 Cosentyx Novartis Pharmaceuticals Canada Inc. N/A 2015-02-27 2021-02-27 Yes 2023-08-27 selexipag 182114 Uptravi Janssen Inc zithromax for urinary tract . N/A 2016-01-20 2022-01-20 N/A 2024-01-20 selpercatinib 243748 Retevmo Loxo Oncology Inc.

N/A 2021-06-15 2027-06-15 Yes 2029-12-15 semaglutide 202059 Ozempic Novo Nordisk Canada Inc. Rybelsus 2018-01-04 2024-01-04 N/A zithromax for urinary tract 2026-01-04 siltuximab 174291 Sylvant EUSA Pharma (UK) Limited N/A 2014-12-03 2020-12-03 N/A 2022-12-03 simeprevir 164021 Galexos Janssen Inc. N/A 2013-11-18 2019-11-18 N/A 2021-11-18 siponimod 223225 Mayzent Novartis Pharmaceuticals Canada Inc.

N/A 2020-02-20 2026-02-20 N/A 2028-02-20 sodium zirconium cyclosilicate 218799 Lokelma AstraZeneca Canada Inc. N/A 2019-07-25 2025-07-25 N/A 2027-07-25 sofosbuvir 165043 zithromax for urinary tract Sovaldi Gilead Sciences Canada Inc. HarvoniEpclusaVosevi 2013-12-13 2019-12-13 N/A 2021-12-13 solriamfetol hydrochloride 237511 Sunosi Jazz Pharmaceuticals Ireland Ltd.

N/A 2021-05-13 2027-05-13 N/A 2029-11-13 sonidegib phosphate 229407 Odomzo Sun Pharma Global FZE N/A 2020-06-12 2026-06-12 N/A 2028-06-12 sucroferric oxyhydroxide 201492 Velphoro Vifor Fresenius Medical Care Renal Pharma Ltd. N/A 2018-01-05 2024-01-05 N/A 2026-01-05 sugammadex sodium 180385 Bridion Merck Canada Inc zithromax for urinary tract . N/A 2016-02-05 2022-02-05 N/A 2024-02-05 suvorexant 196367 Belsomra Merck Canada Inc.

N/A 2018-11-29 2024-11-29 N/A 2026-11-29 tafamidis meglumine 228368 Vyndaqel Pfizer Canada ULC N/A 2020-01-20 2026-01-20 N/A 2028-01-20 tafluprost 165596 Saflutan Purdue Pharma N/A 2014-05-26 2020-05-26 N/A 2022-05-26 talazoparib (supplied as talazoparib tosylate) 220584 Talzenna Pfizer Canada ULC N/A 2019-09-06 2025-09-06 N/A 2027-09-06 taliglucerase alfa 140854 Elelyso Pfizer Canada Inc. N/A 2014-05-29 2020-05-29 zithromax for urinary tract Yes 2022-11-29 tedizolid phosphate 173603 Sivextro Merck Canada Inc. N/A 2015-03-17 2021-03-17 N/A 2023-03-17 teduglutide 180223 Revestive Takeda Canada Inc.

N/A 2015-09-04 2021-09-04 Yes 2024-03-04 telotristat ethyl (as telotristat etiprate) 208730 Xermelo Ipsen Biopharmaceuticals Canada Inc. N/A 2018-10-10 2024-10-10 N/A 2026-10-10 tenapanor hydrochloride 224850 Ibsrela Knight Therapeutics Inc zithromax for urinary tract . N/A 2020-04-15 2026-04-15 N/A 2028-04-15 tenofovir alafenamide hemifumarate 181399 Genvoya Gilead Sciences Canada Inc.

DescovyOdefseyVemlidySymtuzaBiktarvy 2015-11-27 2021-11-27 Yes zithromax for urinary tract 2024-05-27 tepotinib (supplied as tepotinib hydrochloride) 242300 Tepmetko EMD Serono, a Division of EMD Inc., Canada N/A 2021-05-27 2027-05-27 N/A 2029-05-27 teriflunomide 160646 Aubagio Genzyme Canada a division of Sanofi-aventis Canada Inc. N/A 2013-11-14 2019-11-14 Yes 2022-05-14 tesamorelin 131836 Egrifta Theratechnologies Inc. N/A 2014-04-29 2020-04-29 N/A 2022-04-29 tezacaftor 211292 Symdeko Vertex Pharmaceuticals (Canada) Incorporated N/A 2018-06-27 2024-06-27 Yes 2026-12-27 tildrakizumab 224036 Ilumya Sun Pharma Global FZE N/A 2021-05-19 2027-05-19 N/A 2029-05-19 tisagenlecleucel 213547 / 213698 Kymriah Novartis Pharmaceuticals Canada Inc.

N/A 2018-09-05 2024-09-05 Yes 2027-03-05 tofacitinib 154642 zithromax for urinary tract Xeljanz Pfizer Canada Inc. N/A 2014-04-17 2020-04-17 Yes 2022-10-17 trametinib 157665 Mekinist Novartis Pharmaceuticals Canada Inc. N/A 2013-07-18 2019-07-18 N/A 2021-07-18 trastuzumab deruxtecan 242104 Enhertu AstraZeneca Canada Inc.

N/A 2021-04-15 2027-04-15 N/A 2029-04-15 trastuzumab emtansine 162414 Kadcyla Hoffmann-La Roche Limited N/A 2013-09-11 2019-09-11 N/A 2021-09-11 trifarotene 221945 Aklief Galderma Canada Inc. N/A 2019-11-25 2025-11-25 Yes 2028-05-25 tipiracil hydrochloride 205852 Lonsurf Taiho Pharma Canada Inc. N/A 2018-01-25 2024-01-25 N/A 2026-01-25 triheptanoin 242196 Dojolvi Uagenyx Pharmaceutical Inc.

N/A 2021-02-15 2027-02-15 Yes 2029-08-15 tucatinib 235295 Tukysa Seattle Genetics Inc. N/A 2020-06-05 2026-06-05 N/A 2028-06-05 turoctocog alfa 170796 Zonovate Novo Nordisk Canada Inc. N/A 2014-12-08 2020-12-08 Yes 2023-06-08 umeclidinium bromide 161585 Anoro Ellipta GlaxoSmithKline Inc.

Incruse Ellipta 2013-12-23 2019-12-23 N/A 2021-12-23 upadacitinib 223734 Rinvoq AbbVie Corporation N/A 2019-12-23 2025-12-23 N/A 2027-12-23 varicella-zoster zithromax glycoprotein E (gE) 200244 Shingrix GlaxoSmithKline Inc. N/A 2017-10-13 2023-10-13 N/A 2025-10-13 vedolizumab 169414 Entyvio Takeda Canada Inc. N/A 2015-01-29 2021-01-29 Yes 2023-07-29 velpatasvir 190521 Epclusa Gilead Sciences Canada Inc.

Vosevi 2016-07-11 2022-07-11 Yes 2025-01-11 venetoclax 190761 Venclexta AbbVie Corporation N/A 2016-09-30 2022-09-30 N/A 2024-09-30 vernakalant hydrochloride 190817 Brinavess Cipher Pharmaceuticals Inc. N/A 2017-03-13 2023-03-13 N/A 2025-03-13 vilanterol trifenatate 157301 Breo Ellipta GlaxoSmithKline Inc. Anoro ElliptaTrelegy Ellipta 2013-07-03 2019-07-03 Yes 2022-01-03 vilazodone hydrochloride 176820 Viibryd Allergan Inc.

N/A 2015-07-16 2021-07-16 Yes 2024-01-16 vismodegib 154608 Erivedge Hoffmann-La Roche Ltd. N/A 2013-07-12 2019-07-12 N/A 2021-07-12 von willebrand factor (recombinant) (vonicog alfa) 213188 Vonvendi Takeda Canada Inc. N/A 2019-01-10 2025-01-10 N/A 2027-01-10 vorapaxar sulfate 179320 Zontivity Toprol Acquisition LLC N/A 2016-05-13 2022-05-13 N/A 2024-05-13 voretigene neparvovec 233097 Luxturna Novartis Pharmaceuticals Canada Inc.

N/A 2020-10-13 2026-10-13 Yes 2029-04-13 vortioxetine hydrobromide 159019 Trintellix Lundbeck Canada Inc. N/A 2014-10-22 2020-10-22 Yes 2023-04-22 voxilaprevir 202324 Vosevi Gilead Sciences Canada Inc. N/A 2017-08-16 2023-08-16 N/A 2025-08-16 zanubrutinib 242748 Brukinsa BeiGene Switzerland GmbH N/A 2021-03-01 2027-03-01 N/A 2029-03-01.

Abemaciclib 215268 Verzenio Eli Lilly Canada zithromax discount card Inc. N/A 2019-04-08 2025-04-08 N/A 2027-04-08 acalabrutinib 214504 Calquence AstraZeneca Canada Inc. N/A 2019-08-23 2025-08-23 N/A 2027-08-23 zithromax discount card aclidinium bromide 157598 Tudorza Genuair AstraZeneca Canada Inc.

Duaklir Genuair 2013-07-29 2019-07-29 N/A 2021-07-29 afatinib dimaleate 158730 Giotrif Boehringer Ingelheim (Canada) Ltd. N/A 2013-11-01 2019-11-01 N/A 2021-11-01 aflibercept 149321 Eylea Bayer Inc. N/A 2013-11-08 2019-11-08 N/A 2021-11-08 albiglutide 165145 zithromax discount card Eperzan GlaxoSmithKline Inc.

N/A 2015-07-15 2021-07-15 N/A 2023-07-15 alectinib hydrochloride 189442 Alecensaro Hoffmann-La Roche Limited N/A 2016-09-29 2022-09-29 N/A 2024-09-29 alirocumab 183116 Praluent Sanofi-aventis Canada Inc. N/A 2016-04-11 2022-04-11 N/A 2024-04-11 alogliptin benzoate 158335 Nesina Takeda Canada Inc. KazanoOseni 2013-11-27 zithromax discount card 2019-11-27 N/A 2021-11-27 alpelisib 226941 Piqray Novartis Pharmaceuticals Canada Inc.

N/A 2020-03-11 2026-03-11 N/A 2028-03-11 amifampridine (supplied as amifampridine phosphate) 232685 Firdapse Kye Pharmaceuticals Inc. N/A 2020-07-31 2026-07-31 N/A 2028-07-31 anthrax immune globulin (human) 200446 Anthrasil Emergent BioSolutions Canada Inc. N/A 2017-11-06 2023-11-06 Yes 2026-05-06 antihemophilic factor (recombinant BDD), Fc fusion protein 163447 zithromax discount card Eloctate Sanofi-Aventis Canada Inc.

N/A 2014-08-22 2020-08-22 Yes 2023-02-22 antihemophilic factor (recombinant), pegylated 189709 Adynovate Takeda Canada Inc. N/A 2016-11-17 2022-11-17 Yes 2025-05-17 antihemophilic factor (recombinant, B-domain deleted, pegylated) (also known as damoctocog alfa pegol) 210935 Jivi Bayer Inc. N/A 2018-10-18 2024-10-18 Yes 2027-04-18 antihemophilic factor (recombinant, B-domain deleted) (also known as simoctocog alfa) 169551 Nuwiq Octapharma Pharmazeutika Produktionsges.m.b.H N/A 2014-10-23 2020-10-23 Yes 2023-04-23 antihemophilic factor VIII (recombinant), singlechain (also known as lonoctocog alfa) 190891 Afstyla zithromax discount card CSL Behring Canada Inc.

N/A 2016-12-12 2022-12-12 Yes 2025-06-12 anthrax antigen fiate 212387 Biothrax Emergent Biodefense Operations Lansing LLC N/A 2018-12-13 2024-12-13 N/A 2026-12-13 antihemophilic factor VIII (recombinant, B-domain truncated), PEGylated (turoctocog alfa pegol) 218531 Esperoct Novo Nordisk Canada Inc. N/A 2019-07-04 2025-07-04 Yes 2028-01-04 apalutamide 211942 Erleada Janssen Inc. N/A 2018-07-03 zithromax discount card 2024-07-03 N/A 2026-07-03 apremilast 169862 Otezla Amgen Canada Inc.

N/A 2014-11-12 2020-11-12 N/A 2022-11-12 asfotase alfa 179340 Strensiq Alexion Pharma International SÃ rl N/A 2015-08-14 2021-08-14 Yes 2024-02-14 asunaprevir 172617 Sunvepra Bristol-Myers Squibb Canada N/A 2016-03-09 2022-03-09 N/A 2024-03-09 atezolizumab 196843 Tecentriq Hoffmann-La Roche Limited N/A 2017-04-12 2023-04-12 N/A 2025-04-12 avelumab 204052 Bavencio EMD Serono, a Division of EMD Inc., Canada N/A 2017-12-18 2023-12-18 N/A 2025-12-18 axicabtagene ciloleucel 218389 Yescarta Gilead Sciences Canada Inc N/A 2019-02-13 2025-02-13 N/A 2027-02-13 azelastine hydrochloride 169604 Dymista Meda Pharmaceuticals Ltd. N/A 2014-10-23 2020-10-23 Yes 2023-04-23 baloxavir marboxil 227361 Xofluza Hoffmann-La Roche Limited N/A 2020-02-19 2026-02-19 Yes 2028-08-19 baricitinib 193687 Olumiant Eli Lilly Canada Inc. N/A 2018-08-17 2024-08-17 N/A 2026-08-17 bazedoxifene acetate 160681 Duavive zithromax discount card Pfizer Canada Inc.

N/A 2016-04-21 2022-04-21 Yes 2024-10-21 binimetinib 237410 Mektovi Pfizer Canada ULC N/A 2021-03-02 2027-03-02 N/A 2029-03-02 blinatumomab 181723 Blincyto Amgen Canada Incorporated N/A 2015-12-22 2021-12-22 Yes 2024-06-22 bosutinib 152211 Bosulif Pfizer Canada Inc. N/A 2014-03-07 2020-03-07 N/A 2022-03-07 zithromax discount card botulism antitoxin heptavalen C/ D/ F/ G - (equine) 190645 Bat Emergent BioSolutions Inc. N/A 2016-12-08 2022-12-08 Yes 2025-06-08 brexpiprazole 192684 Rexulti Otsuka Pharmaceutical Co.

Ltd. N/A 2017-02-16 2023-02-16 Yes 2025-08-16 brexucabtagene autoleucel 246355 Tecartus Gilead Sciences Canada, zithromax discount card Inc. N/A 2021-06-08 2027-06-08 N/A 2029-06-08 brigatinib 210369 Alunbrig Takeda Canada Incorporated N/A 2018-07-26 2024-07-26 N/A 2026-07-26 brivaracetam 183355 Brivlera UCB Canada Incorporated N/A 2016-03-09 2022-03-09 Yes 2024-09-09 brodalumab 195317 Siliq Bausch Health, Canada Inc.

N/A 2018-03-06 2024-03-06 N/A 2026-03-06 brolucizumab 226224 Beovu Novartis Pharmaceuticals Canada Inc. N/A 2020-03-12 2026-03-12 N/A zithromax discount card 2028-03-12 bromfenac sodium sesquihydrate 171657 Prolensa Bausch &. Lomb Incorporated N/A 2015-03-26 2021-03-26 N/A 2023-03-26 burosumab 216239 Crysvita Kyowa Kirin Limited N/A 2018-12-05 2024-12-05 Yes 2027-06-05 cabotegravir sodium 227315 Vocabria ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabotegravir 227315 Cabenuva ViiV Healthcare ULC N/A 2020-03-18 2026-03-18 N/A 2028-03-18 cabozantinib (supplied as cabozantinib (S)-malate) 206230 Cabometyx Ipsen Biopharmaceuticals Canada Inc.

N/A 2018-09-14 2024-09-14 N/A 2026-09-14 calcifediol 205392 Rayaldee Vifor Fresenius Medical Care Renal Pharma Ltd N/A 2018-07-10 2024-07-10 N/A 2026-07-10 canagliflozin 157505 Invokana Janssen Inc. InvokametInvokamet XR 2014-05-23 2020-05-23 N/A 2022-05-23 caplacizumab zithromax discount card 230001 Cablivi Sanofi-Aventis Canada Inc. N/A 2020-02-28 2026-02-28 N/A 2028-02-28 carfilzomib 184479 Kyprolis Amgen Canada Inc.

N/A 2016-01-15 2022-01-15 N/A 2024-01-15 carglumic acid 171358 Carbaglu Recordati Rare Diseases N/A 2015-04-10 2021-04-10 Yes 2023-10-10 cedazuridine 234610 Inqovi Otsuka Pharmaceutical Co., Ltd. N/A 2020-07-07 2026-07-07 N/A 2028-07-07 ceftolozane zithromax discount card 178006 Zerbaxa Merck Canada Inc. N/A 2015-09-30 2021-09-30 N/A 2023-09-30 cemiplimab 218718 Libtayo Sanofi-Aventis Canada Inc.

N/A 2019-04-10 2025-04-10 N/A 2027-04-10 cenegermin 218145 Oxervate DompÃ© farmaceutici S.p.A. N/A 2019-02-08 2025-02-08 N/A 2027-02-08 zithromax discount card ceritinib 175702 Zykadia Novartis Pharmaceuticals Canada Inc. N/A 2015-03-27 2021-03-27 N/A 2023-03-27 cerliponase alfa 216539 Brineura Biomarin International Limited N/A 2018-12-19 2024-12-19 Yes 2027-06-19 coagulation factor IX (recombinant), albumin fusion protein (rIX-FP) 180793 Idelvion CSL Behring Canada Inc.

N/A 2016-01-26 2022-01-26 Yes 2024-07-26 coagulation factor IX (recombinant), pegylated (nonacog beta pegol) 201114 Rebinyn Novo Nordisk Canada Inc. N/A 2017-11-29 2023-11-29 Yes 2026-05-29 coagulation factor IX, Fc zithromax discount card fusion protein 163614 Alprolix Sanofi-Aventis Canada Inc. N/A 2014-03-20 2020-03-20 Yes 2022-09-20 cobimetinib 182788 Cotellic Hoffmann-La Roche Limited N/A 2016-02-22 2022-02-22 N/A 2024-02-22 crisaborole 206906 Eucrisa Pfizer Canada Inc.

N/A 2018-06-07 2024-06-07 Yes 2026-12-07 cysteamine bitartrate 191347 Procysbi Horizon Pharma Ireland Ltd. N/A 2017-06-13 2023-06-13 Yes 2025-12-13 dabrafenib mesylate 157590 Tafinlar Novartis Pharmaceuticals zithromax discount card Canada Inc. N/A 2013-07-16 2019-07-16 N/A 2021-07-16 daclatasvir 172616 Daklinza Bristol-Myers Squibb Canada N/A 2015-08-13 2021-08-13 N/A 2023-08-13 daclizumab beta 190458 Zinbryta Biogen Canada Inc.

N/A 2016-12-08 2022-12-08 N/A 2024-12-08 zithromax discount card dacomitinib 214572 Vizimpro Pfizer Canada Inc. N/A 2019-02-26 2025-02-26 N/A 2027-02-26 dalbavancin (supplied as dalbavancin hydrochloride) 212390 Xydalba Cipher Pharmaceuticals Inc. N/A 2018-09-04 2024-09-04 N/A 2026-09-04 dapagliflozin propanediol 160877 Forxiga AstraZeneca Canada Inc.

XigduoQtern 2014-12-12 2020-12-12 N/A zithromax discount card 2022-12-12 daratumumab 187648 Darzalex Janssen Inc. Darzalex SC 2016-06-29 2022-06-29 N/A 2024-06-29 darolutamide 226146 Nubeqa Bayer Inc. N/A 2020-02-20 2026-02-20 N/A 2028-02-20 deferiprone 162924 Ferriprox Chiesi Canada Corp.

N/A 2015-02-13 2021-02-13 Yes 2023-08-13 defibrotide sodium 200808 Defitelio Jazz Pharmaceuticals Ireland Limited N/A 2017-07-10 2023-07-10 zithromax discount card Yes 2026-01-10 difluprednate 154517 Durezol Novartis Pharmaceuticals Canada Inc. N/A 2013-11-04 2019-11-04 Yes 2022-05-04 dimethyl fumarate 154776 Tecfidera Biogen Idec Canada Inc. N/A 2013-04-03 2019-04-03 Yes 2021-10-03 dinutuximab 212066 Unituxin United Therapeutics Corporation N/A 2018-11-28 2024-11-28 Yes 2027-05-28 dolutegravir sodium 161084 Tivicay ViiV Healthcare ULC TriumeqJulucaDovato 2013-10-31 2019-10-31 Yes 2022-05-01 doravirine 211293 Pifeo Merck Canada Inc.

Delstrigo 2018-10-12 2024-10-12 N/A zithromax discount card 2026-10-12 dulaglutide 168671 Trulicity Eli Lilly Canada Inc. N/A 2015-11-10 2021-11-10 N/A 2023-11-10 dupilumab 201285 Dupixent Sanofi-Aventis Canada Inc. N/A 2017-11-30 2023-11-30 Yes 2026-05-30 durvalumab 202953 Imfinzi AstraZeneca Canada Inc.

N/A 2017-11-03 2023-11-03 N/A 2025-11-03 edaravone 214391 Radicava Mitsubishi Tanabe Pharma Corporation N/A 2018-10-03 2024-10-03 N/A 2026-10-03 edoxaban zithromax discount card 187363 Lixiana Servier Canada Inc. N/A 2016-11-04 2022-11-04 N/A 2024-11-04 efinaconazole 159416 Jublia Bausch Health, Canada Inc. N/A 2013-10-02 2019-10-02 N/A 2021-10-02 elagolix 209513 Orilissa AbbVie Corporation N/A 2018-10-05 2024-10-05 N/A 2026-10-05 elexacaftor 246955 Trikafta Vertex Pharmaceuticals (Canada) Incorporated N/A 2021-06-18 2027-06-18 Yes 2029-12-18 eliglustat tartrate 183050 Cerdelga Genzyme Canada, A division of Sanofi-aventis Canada Inc.

N/A 2017-04-21 2023-04-21 N/A 2025-04-21 elosulfase alfa 170340 Vimizim Biomarin International zithromax discount card Limited N/A 2014-07-02 2020-07-02 Yes 2023-01-02 elotuzumab 188144 Empliciti Bristol-Myers Squibb Canada N/A 2016-06-21 2022-06-21 N/A 2024-06-21 eluxadoline 190162 Viberzi Allergan inc. N/A 2017-01-26 2023-01-26 N/A 2025-01-26 emicizumab 212635 Hemlibra Hoffmann-La Roche Limited N/A 2018-08-02 2024-08-02 Yes 2027-02-02 empagliflozin 162552 Jardiance Boehringer Ingelheim (Canada) Ltd. SynjardyGlyxambi 2015-07-23 2021-07-23 N/A 2023-07-23 enasidenib mesylate 217033 Idhifa Celgene Inc.

N/A 2019-02-06 2025-02-06 N/A 2027-02-06 encorafenib 237413 Braftovi Pfizer Canada ULC N/A 2021-03-02 zithromax discount card 2027-03-02 N/A 2029-03-02 entrectinib 227517 Rozlytrek Hoffmann-La Roche Limited N/A 2020-02-10 2026-02-10 Yes 2028-08-10 eptinezumab 233288 Vyepti Lundbeck Canada Inc. N/A 2021-01-11 2027-01-11 N/A 2029-01-11 erdafitinib 224529 Balversa Janssen Inc. N/A 2019-10-25 2025-10-25 N/A 2027-10-25 erenumab 208607 Aimovig Novartis Pharmaceuticals Canada Inc.

N/A 2018-08-01 2024-08-01 N/A zithromax discount card 2026-08-01 ertugliflozin 204724 Steglatro Merck Canada Inc. SteglujanSegluromet 2018-05-09 2024-05-09 N/A 2026-05-09 eslicarbazepine acetate 165665 Aptiom Sunovion Pharmaceuticals Canada Inc. N/A 2014-07-08 zithromax discount card 2020-07-08 Yes 2023-01-08 estetrol monohydrate 236197 Nextstellis Searchlight Pharma Inc.

N/A 2021-03-05 2027-03-05 N/A 2029-03-05 evolocumab 178234 Repatha Amgen Canada Inc. N/A 2015-09-10 2021-09-10 Yes 2024-03-10 fedratinib (supplied as fedratinib hydrochloride) 229866 Inrebic Celgene Inc. N/A 2020-07-27 zithromax discount card 2026-07-27 N/A 2028-07-27 ferric pyrophosphate citrate 239850 Triferic Avnu Rockwell Medical Inc.

N/A 2018-03-22 2024-03-22 N/A 2026-03-22 fostamatinib (supplied as fostamatinib disodium) 232078 Tavalisse Rigel Pharmaceuticals Inc. N/A 2020-11-19 2026-11-19 N/A 2028-11-19 fremanezumab 226828 Ajovy Teva Canada Limited N/A 2020-04-09 2026-04-09 N/A 2028-04-09 gadoterate meglumine 186333 Dotarem Guerbet N/A 2016-11-26 2022-11-26 Yes 2025-05-26 galcanezumab 219521 Emgality Eli Lilly Canada Inc. N/A 2019-07-30 2025-07-30 zithromax discount card N/A 2027-07-30 galsulfase 159020 Naglazyme BioMarin Pharmaceutical Inc.

N/A 2013-09-16 2019-09-16 Yes 2022-03-16 gemtuzumab ozogamicin 223091 Mylotarg Pfizer Canada ULC N/A 2019-11-28 2025-11-28 Yes 2028-05-28 gilteritinib fumarate 227918 Xospata Astellas Pharma Canada Inc. N/A 2019-12-23 2025-12-23 N/A 2027-12-23 givosiran (supplied as givosiran sodium) 237194 Givlaari Alnylam Netherlands B.V.. N/A 2020-10-09 2026-10-09 N/A 2028-10-09 glasdegib 225793 Daurismo zithromax discount card Pfizer Canada ULC N/A 2020-04-28 2026-04-28 N/A 2028-04-28 glecaprevir, pibrentasvir 202233 Maviret AbbVie Corporation N/A 2017-08-16 2023-08-16 Yes 2026-02-16 glycerol phenylbutyrate 174219 Ravicti Horizon Pharma Ireland Ltd.

N/A 2016-03-18 2022-03-18 Yes 2024-09-18 grazoprevir, elbasvir 185866 Zepatier Merck Canada Inc. N/A 2016-01-19 2022-01-19 N/A 2024-01-19 guanfacine hydrochloride 150741 Intuniv XR Takeda Canada Inc. N/A 2013-07-05 2019-07-05 Yes 2022-01-05 guselkumab zithromax discount card 200590 Tremfya Janssen Inc.

N/A 2017-11-10 2023-11-10 N/A 2025-11-10 haemagglutinin strain A (H5N1) 115398 Arepanrix H5N1 ID Biomedical Corporation of Quebec N/A 2013-02-13 2019-02-13 Yes 2021-08-13 hemin 212276 Panhematin Recordati Rare Diseases Canada Inc. N/A 2018-07-13 2024-07-13 N/A 2026-07-13 ibrutinib 174029 Imbruvica Janssen Inc. N/A 2014-11-17 2020-11-17 Yes 2023-05-17 zithromax discount card icatibant acetate 162918 Firazyr Takeda Canada Inc.

N/A 2014-06-04 2020-06-04 Yes 2022-12-04 icosapent ethyl 227235 Vascepa HLS Therapeutics Inc. N/A 2019-12-30 2025-12-30 N/A 2027-12-30 idarucizumab 182503 Praxbind Boehringer Ingelheim (Canada) Ltd N/A 2016-04-29 2022-04-29 N/A 2024-04-29 idecabtagene vicleucel 244266 Abecma Celgene Inc. N/A 2021-05-26 2027-05-26 N/A 2029-05-26 idelalisib 172652 Zydelig Gilead zithromax discount card Sciences Canada Inc.

N/A 2015-03-27 2021-03-27 N/A 2023-03-27 inotersen sodium 214274 Tegsedi Akcea Therapeutics Inc. N/A 2018-10-03 2024-10-03 N/A 2026-10-03 inotuzumab ozogamicin 204077 Besponsa zithromax discount card Pfizer Canada Inc. N/A 2018-03-15 2024-03-15 N/A 2026-03-15 insulin degludec 198124 Tresiba Novo Nordisk Canada Inc.

Xultophy 2017-08-25 2023-08-25 Yes 2026-02-25 ioflupane (123I) 201481 Datscan GE Healthcare Canada Inc. N/A 2017-12-07 2023-12-07 N/A 2025-12-07 zithromax discount card iron isomaltoside 1000 193890 Monoferric Pharmacosmos A/S N/A 2018-06-22 2024-06-22 N/A 2026-06-22 isatuximab 229245 Sarclisa Sanofi-Aventis Canada Inc. N/A 2020-04-29 2026-04-29 N/A 2028-04-29 isavuconazole (supplied as isavuconazonium sulfate) 208919 Cresemba Avir Pharma Inc.

N/A 2018-12-19 2024-12-19 N/A 2026-12-19 ivabradine hydrochloride 166949 Lancora Servier Canada Inc. N/A 2016-12-23 zithromax discount card 2022-12-23 Yes 2025-06-23 ivermectin 172733 Rosiver Galderma Canada Inc. N/A 2015-04-22 2021-04-22 N/A 2023-04-22 ixazomib (supplied as ixazomib citrate) 190498 Ninlaro Takeda Canada Inc.

N/A 2016-08-04 2022-08-04 N/A 2024-08-04 ixekizumab 184993 Taltz Eli Lilly Canada Inc. N/A 2016-05-25 2022-05-25 Yes 2024-11-25 lanadelumab 213920 Takhzyro Takeda zithromax discount card Canada Inc. N/A 2018-09-19 2024-09-19 Yes 2027-03-19 larotrectinib (supplied as larotrectinib sulfate) 219998 Vitrakvi Bayer Inc.

N/A 2019-07-10 2025-07-10 Yes 2028-01-10 latanoprostene bunod 211732 Vyzulta Bausch &. Lomb Incorporated N/A zithromax discount card 2018-12-27 2024-12-27 N/A 2026-12-27 ledipasvir 173180 Harvoni Gilead Sciences Canada Inc. N/A 2014-10-15 2020-10-15 Yes 2023-04-15 lefamulin acetate 233292 Xenleta Sunovion Pharmaceuticals Canada Inc.

N/A 2020-07-10 2026-07-10 N/A 2028-07-10 lemborexant 231286 Dayvigo Eisai Limited N/A 2020-11-04 2026-11-04 N/A 2028-11-04 lenvatinib mesylate 180877 Lenvima Eisai Limited N/A 2015-12-22 2021-12-22 N/A 2023-12-22 letermovir 204165 Prevymis Merck Canada Inc. N/A 2017-11-01 2023-11-01 N/A 2025-11-01 levomilnacipran hydrochloride 167319 Fetzima Allergan Inc zithromax discount card. N/A 2015-05-08 2021-05-08 N/A 2023-05-08 lifitegrast 199810 Xiidra Novartis Pharmaceuticals Canada Inc.

N/A 2017-12-22 2023-12-22 N/A 2025-12-22 linaclotide 161056 Constella Forest Laboratories Canada Inc. N/A 2013-12-02 2019-12-02 N/A 2021-12-02 zithromax discount card lixisenatide 193862 Adlyxine Sanofi-aventis Canada Inc. Soliqua 2017-05-25 2023-05-25 N/A 2025-05-25 lomitapide mesylate 160385 Juxtapid Aegerion Pharmaceuticals Canada Ltd.

N/A 2014-02-04 2020-02-04 N/A 2022-02-04 lorlatinib 215733 Lorbrena Pfizer Canada ULC N/A 2019-02-22 2025-02-22 N/A 2027-02-22 lubiprostone 179333 Amitiza Sucampo Pharma Americas LLC N/A 2015-10-14 2021-10-14 N/A 2023-10-14 lumacaftor 181715 Orkambi Vertex Pharmaceuticals (Canada) Incorporated N/A 2016-01-26 2022-01-26 Yes 2024-07-26 luspatercept 236441 Reblozyl Celgene Inc. N/A 2020-09-25 2026-09-25 N/A 2028-09-25 lutetium177 Lu oxodotreotide zithromax discount card 217184 Lutathera Advanced Accelerator Applications USA, Inc. N/A 2019-01-09 2025-01-09 N/A 2027-01-09 macitentan 161372 Opsumit Janssen Inc.

N/A 2013-11-06 2019-11-06 Yes 2022-05-06 zithromax discount card mecasermin 235023 Increlex Ipsen Biopharmaceuticals Canada Inc. N/A 2020-12-17 2026-12-17 Yes 2029-06-17 mepolizumab 179850 Nucala GlaxoSmithKline Inc. N/A 2015-12-03 2021-12-03 Yes 2024-06-03 midostaurin 201101 Rydapt Novartis Pharmaceuticals Canada Inc.

N/A 2017-07-21 2023-07-21 Yes 2026-01-21 mifepristone 160063 Mifegymiso Linepharma International Limited N/A 2015-07-29 2021-07-29 Yes 2024-01-29 migalastat hydrochloride 196956 Galafold Amicus Therapeutics UK LTD N/A 2017-09-05 2023-09-05 N/A 2025-09-05 modified vaccinia zithromax (ankara-bavarian nordic) 144762 Imvamune Bavarian Nordic A/S N/A 2013-11-21 2019-11-21 N/A 2021-11-21 naloxegol oxalate 167790 Movantik Knight zithromax discount card Therapeutics Inc. N/A 2015-06-02 2021-06-02 N/A 2023-06-02 necitumumab 193689 Portrazza Eli Lilly Canada Inc. N/A 2017-03-16 2023-03-16 N/A 2025-03-16 neisseria meningitidis serogroup A polysaccharide, neisseria meningitidis serogroup C polysaccharide, neisseria meningitidis serogroup W-135 polysaccharide, neisseria meningitidis serogroup Y polysaccharide, conjugated to tetanus toxoid carrier protein 154290 Nimenrix Pfizer Canada Inc.

N/A 2013-03-05 2019-03-05 Yes 2021-09-05 neisseria meningitidis serogroup B recombinant lipoprotein 2086 (rLP2086) subfamily A and Neisseria meningitidis serogroup B recombinant lipoprotein 2086 (rLP2086) subfamily B 195550 Trumenba zithromax discount card Pfizer Canada Inc. N/A 2017-10-05 2023-10-05 Yes 2026-04-05 neratinib maleate 218224 Nerlynx Knight Therapeutics Inc. N/A 2019-07-16 2025-07-16 N/A 2027-07-16 netupitant 196495 Akynzeo Elvium Life Sciences N/A 2017-09-28 2023-09-28 N/A 2025-09-28 nintedanib (supplied as nintedanib esilate) 176043 Ofev Boehringer Ingelheim (Canada) Ltd N/A 2015-06-25 2021-06-25 N/A 2023-06-25 niraparib 216792 Zejula GlaxoSmithKline Inc.

N/A 2019-06-27 2025-06-27 N/A 2027-06-27 zithromax discount card nivolumab 180828 Opdivo Bristol-Myers-Squibb Canada N/A 2015-09-25 2021-09-25 Yes 2024-03-25 nusinersen 200070 Spinraza Biogen Canada Inc. N/A 2017-06-29 2023-06-29 Yes 2025-12-29 obeticholic acid 198418 Ocaliva Intercept Pharmaceuticals Inc. N/A 2017-05-24 2023-05-24 N/A 2025-05-24 obiltoxaximab 230825 Anthim Elusys Therapeutics, Inc.

N/A 2020-07-30 2026-07-30 N/A 2028-07-30 obinutuzumab 168227 Gazyva Hoffmann-La Roche Limited zithromax discount card N/A 2014-11-25 2020-11-25 N/A 2022-11-25 ocrelizumab 198094 Ocrevus Hoffmann-La Roche Limited N/A 2017-08-14 2023-08-14 N/A 2025-08-14 ocriplasmin 161356 Jetrea ThromboGenics N.V. N/A 2013-08-13 2019-08-13 N/A 2021-08-13 olaparib 182823 Lynparza AstraZeneca Canada Inc. N/A 2016-04-29 2022-04-29 N/A 2024-04-29 olaratumab 203478 Lartruvo Eli Lilly Canada Inc.

N/A 2017-11-23 2023-11-23 N/A 2025-11-23 ombitasvir, paritaprevir, dasabuvir sodium 174739 Holkira Pak Abbvie Corporation Technivie 2014-12-22 2020-12-22 N/A 2022-12-22 onasemnogene zithromax discount card abeparvovec 239719 Zolgensma Novartis Pharmaceuticals Canada Inc. N/A 2020-12-15 2026-12-15 Yes 2029-06-15 osimertinib mesylate 188171 Tagrisso AstraZeneca Canada Inc. N/A 2016-07-05 2022-07-05 N/A 2024-07-05 ozanimod (supplied as ozanimod hydrochloride) 232761 Zeposia Celgene Inc.

N/A 2020-10-02 2026-10-02 N/A 2028-10-02 ozenoxacin zithromax discount card 192925 Ozanex Ferrer Internacional, S.A. N/A 2017-05-01 2023-05-01 Yes 2025-11-01 palbociclib 182048 Ibrance Pfizer Canada Inc. N/A 2016-03-16 2022-03-16 N/A 2024-03-16 pasireotide diaspartate 145005 Signifor Novartis Pharmaceuticals Canada Inc.

Signifor Lar 2013-09-23 2019-09-23 N/A 2021-09-23 patiromer sorbitex calcium 210368 Veltassa Vifor Fresenius Medical Care Renal Pharma Ltd zithromax discount card. N/A 2018-10-03 2024-10-03 N/A 2026-10-03 patisiran (as patisiran sodium) 221896 Onpattro Alnylam Netherlands B.V. N/A 2019-06-07 zithromax discount card 2025-06-07 N/A 2027-06-07 peginterferon beta-1a 166974 Plegridy Biogen Idec Canada Inc.

N/A 2015-08-10 2021-08-10 N/A 2023-08-10 pembrolizumab 175884 Keytruda Merck Canada Inc. N/A 2015-05-19 2021-05-19 Yes 2023-11-19 peramivir 191280 Rapivab BioCryst Pharmaceuticals Inc. N/A 2017-01-05 2023-01-05 N/A 2025-01-05 perampanel 153747 Fycompa Eisai Limited N/A 2013-04-04 2019-04-04 Yes 2021-10-04 pitolisant hydrochloride 238175 Wakik Endo Ventures Ltd zithromax discount card.

N/A 2021-05-25 2027-05-25 N/A 2029-05-25 plecanatide 215288 Trulance Bausch Health, Canada Inc. N/A 2019-10-10 2025-10-10 N/A 2027-10-10 polatuzumab vedotin 232303 Polivy Hoffmann-La Roche Limited N/A 2020-07-09 2026-07-09 N/A 2028-07-09 polidocanol 177359 Varithena Provensis Ltd. N/A 2015-08-04 2021-08-04 N/A zithromax discount card 2023-08-04 pomalidomide 165891 Pomalyst Celgene Inc.

N/A 2014-01-20 2020-01-20 Yes 2022-07-20 pralatrexate 207545 Folotyn Servier Canada Inc. N/A 2018-10-26 2024-10-26 N/A 2026-10-26 pralsetinib 243731 Gavreto Hoffmann-La Roche Limited N/A 2021-06-30 2027-06-30 N/A 2029-06-30 prasterone 198822 Intrarosa Endoceutics Inc. N/A 2019-11-01 2025-11-01 N/A zithromax discount card 2027-11-01 ponatinib hydrochloride 165121 Iclusig Ariad Pharmaceuticals Inc.

N/A 2015-04-02 2021-04-02 N/A 2023-04-02 ponesimod 239537 Ponvory Janssen Inc. N/A 2021-04-28 2027-04-28 N/A 2029-04-28 propiverine hydrochloride 188323 Mictoryl / Mictoryl Pediatric Duchesnay Inc. N/A 2017-01-05 zithromax discount card 2023-01-05 Yes 2025-07-05 radium - 223 dichloride 161312 Xofigo Bayer Inc.

N/A 2013-12-12 2019-12-12 N/A 2021-12-12 ramucirumab 176810 Cyramza Eli Lilly Canada Inc. N/A 2015-07-16 2021-07-16 N/A 2023-07-16 ravulizumab 217955 Ultomiris Alexion Pharma GmbH N/A 2019-08-28 2025-08-28 N/A 2027-08-28 recombinant haemagglutinin protein-strain A (H1N1) recombinant haemagglutinin protein-strain A (H3N2) recombinant haemagglutinin protein-strain B (Victoria) recombinant haemagglutinin protein-strain B (Yamagata) 235672 Supemtek Sanofi Pasteur Limited N/A 2021-01-14 2027-01-14 N/A 2029-01-14 recombinant human papillomazithromax types 31, 33, 45, 52 and 58 170006 Gardasil 9 Merck Canada Inc. N/A 2015-02-05 zithromax discount card 2021-02-05 Yes 2023-08-05 recombinant neisseria meningitidis group B NHBA fusion protein, recombinant neisseria meningitidis group B NadA protein, recombinant neisseria meningitidis group B FHBP fusion protein, outer membrane vesicle (neisseria meningitidis group B NZ98/254 strain) 147275 Bexsero GlaxoSmithKline Inc.

N/A 2013-12-06 2019-12-06 Yes 2022-06-06 recombinant porcine factor VIII (antihemophilic factor (recombinant), porcine sequence) 177290 Obizur Takeda Canada Inc. N/A 2015-10-14 2021-10-14 N/A 2023-10-14 regorafenib monohydrate 157970 Stivarga Bayer Inc. N/A 2013-03-11 2019-03-11 Yes 2021-09-11 zithromax discount card remdesivir 240551 Veklury Gilead Sciences Canada, Inc.

N/A 2013-09-19 2019-09-19 N/A 2021-09-19 ripretinib 234688 Qinlock Deciphera Pharmaceuticals, LLC N/A 2020-06-19 2026-06-19 N/A 2028-06-19 risankizumab 215753 Skyrizi AbbVie Corporation N/A 2019-04-17 2025-04-17 N/A 2027-04-17 risdiplam 242373 Evrysdi Hoffman-La Roche Limited N/A 2021-04-14 2027-04-14 Yes 2029-10-14 romidepsin 152293 Istodax Celgene Inc. N/A 2013-10-16 2019-10-16 N/A 2021-10-16 romosozumab 197713 Evenity Amgen zithromax discount card Canada Inc. N/A 2019-06-17 2025-06-17 N/A 2027-06-17 rupatadine (supplied as rupatadine fumarate) 186488 Rupall Medexus Pharmaceuticals Inc.

N/A 2016-07-20 2022-07-20 Yes 2025-01-20 sacubitril 182734 Entresto Novartis Pharmaceuticals Canada Inc. N/A 2015-10-02 2021-10-02 N/A 2023-10-02 safinamide (as safinamide zithromax discount card mesylate) 207115 Onstryv Valeo Pharma Inc. N/A 2019-01-10 2025-01-10 N/A 2027-01-10 sarilumab 191745 Kevzara Sanofi-aventis Canada Inc.

N/A 2017-01-12 2023-01-12 N/A 2025-01-12 satralizumab 233642 Enspryng Hoffmann-La Roche Limited N/A 2020-06-01 2026-06-01 Yes 2028-12-01 sebelipase alfa 204085 Kanuma Alexion Pharma GmbH N/A 2017-12-15 2023-12-15 Yes 2026-06-15 secukinumab 170732 Cosentyx Novartis Pharmaceuticals Canada Inc. N/A 2015-02-27 2021-02-27 Yes 2023-08-27 zithromax discount card selexipag 182114 Uptravi Janssen Inc. N/A 2016-01-20 2022-01-20 N/A 2024-01-20 selpercatinib 243748 Retevmo Loxo Oncology Inc.

N/A 2021-06-15 2027-06-15 Yes 2029-12-15 semaglutide 202059 Ozempic Novo Nordisk Canada Inc. Rybelsus 2018-01-04 2024-01-04 N/A 2026-01-04 siltuximab 174291 Sylvant EUSA Pharma (UK) Limited N/A 2014-12-03 zithromax discount card 2020-12-03 N/A 2022-12-03 simeprevir 164021 Galexos Janssen Inc. N/A 2013-11-18 2019-11-18 N/A 2021-11-18 siponimod 223225 Mayzent Novartis Pharmaceuticals Canada Inc.

N/A 2020-02-20 2026-02-20 N/A 2028-02-20 sodium zirconium cyclosilicate 218799 Lokelma AstraZeneca Canada Inc. N/A 2019-07-25 2025-07-25 N/A 2027-07-25 sofosbuvir 165043 Sovaldi Gilead zithromax discount card Sciences Canada Inc. HarvoniEpclusaVosevi 2013-12-13 2019-12-13 N/A 2021-12-13 solriamfetol hydrochloride 237511 Sunosi Jazz Pharmaceuticals Ireland Ltd.

N/A 2021-05-13 2027-05-13 N/A 2029-11-13 sonidegib phosphate 229407 Odomzo Sun Pharma Global FZE N/A 2020-06-12 2026-06-12 N/A 2028-06-12 sucroferric oxyhydroxide 201492 Velphoro Vifor Fresenius Medical Care Renal Pharma Ltd. N/A 2018-01-05 2024-01-05 N/A 2026-01-05 sugammadex sodium 180385 Bridion Merck zithromax discount card Canada Inc. N/A 2016-02-05 2022-02-05 N/A 2024-02-05 suvorexant 196367 Belsomra Merck Canada Inc.

N/A 2018-11-29 2024-11-29 N/A 2026-11-29 tafamidis meglumine 228368 Vyndaqel Pfizer Canada ULC N/A 2020-01-20 2026-01-20 N/A 2028-01-20 tafluprost 165596 Saflutan Purdue Pharma N/A 2014-05-26 2020-05-26 N/A 2022-05-26 talazoparib (supplied as talazoparib tosylate) 220584 Talzenna Pfizer Canada ULC N/A 2019-09-06 2025-09-06 N/A 2027-09-06 taliglucerase alfa 140854 Elelyso Pfizer Canada Inc. N/A 2014-05-29 2020-05-29 Yes 2022-11-29 tedizolid phosphate 173603 Sivextro zithromax discount card Merck Canada Inc. N/A 2015-03-17 2021-03-17 N/A 2023-03-17 teduglutide 180223 Revestive Takeda Canada Inc.

N/A 2015-09-04 2021-09-04 Yes 2024-03-04 telotristat ethyl (as telotristat etiprate) 208730 Xermelo Ipsen Biopharmaceuticals Canada Inc. N/A 2018-10-10 2024-10-10 N/A 2026-10-10 tenapanor hydrochloride 224850 Ibsrela Knight Therapeutics Inc. N/A 2020-04-15 2026-04-15 N/A 2028-04-15 tenofovir alafenamide hemifumarate 181399 Genvoya Gilead Sciences Canada Inc.

DescovyOdefseyVemlidySymtuzaBiktarvy 2015-11-27 2021-11-27 Yes 2024-05-27 tepotinib (supplied as tepotinib hydrochloride) 242300 Tepmetko EMD Serono, a Division of EMD Inc., Canada N/A 2021-05-27 2027-05-27 N/A 2029-05-27 teriflunomide 160646 Aubagio Genzyme Canada a division of Sanofi-aventis Canada Inc. N/A 2013-11-14 2019-11-14 Yes 2022-05-14 tesamorelin 131836 Egrifta Theratechnologies Inc. N/A 2014-04-29 2020-04-29 N/A 2022-04-29 tezacaftor 211292 Symdeko Vertex Pharmaceuticals (Canada) Incorporated N/A 2018-06-27 2024-06-27 Yes 2026-12-27 tildrakizumab 224036 Ilumya Sun Pharma Global FZE N/A 2021-05-19 2027-05-19 N/A 2029-05-19 tisagenlecleucel 213547 / 213698 Kymriah Novartis Pharmaceuticals Canada Inc.

N/A 2018-09-05 2024-09-05 Yes 2027-03-05 tofacitinib 154642 Xeljanz Pfizer Canada Inc. N/A 2014-04-17 2020-04-17 Yes 2022-10-17 trametinib 157665 Mekinist Novartis Pharmaceuticals Canada Inc. N/A 2013-07-18 2019-07-18 N/A 2021-07-18 trastuzumab deruxtecan 242104 Enhertu AstraZeneca Canada Inc.

What should my health care professional know before I take Zithromax?

They need to know if you have any of these conditions:;

kidney disease; liver disease
pneumonia
stomach problems (especially colitis)
other chronic illness; an unusual or allergic reaction to azithromycin
other macrolide antibiotics (such as erythromycin), foods, dyes, or preservatives
pregnant or trying to get pregnant
breast-feeding

How fast does zithromax work

WASHINGTON, DC how fast does zithromax work http://www.sainte-cluque.com/cheap-levitra-canada/ â The U.S. Department of Labor today announced its intent to award up to $20 million in grant funding to elevate workersâ rights and improve working conditions in the Central American countries of El Salvador, Guatemala and Honduras. Administered by the Bureau of International Labor Affairs, these funding opportunities will finance projects to promote respect for labor rights and labor rights compliance in the region that are aligned how fast does zithromax work with the Biden-Harris administrationâs Root Causes of Migration Strategy.

The $20 million in available funding includes up to $7 million to address child labor, forced labor and other unacceptable conditions of work among El Salvador, Guatemala and Hondurasâ vulnerable populations, including indigenous communities and people of African descent. The department published a funding opportunity announcement yesterday that will fund this project to improve the ability of communities to come together and collaborate with governments, the how fast does zithromax work private sector and others to address unacceptable work conditions. In the coming weeks, the department will announce an additional $13 million in funding opportunities aimed at improving occupational safety and health conditions, access to social protection services and respect for workersâ rights in Central America.

The administrationâs Root Causes strategy recognizes that decent work and the promotion of labor how fast does zithromax work rights fosters inclusive economic growth. Through ILAB, the department will use its mandate to address issues related to labor rights compliance in the region and engage labor, worker organizations, womenâs empowerment organizations and other organizations in the U.S., El Salvador, Guatemala and Honduras to inform future programming. The regionâs challenges include weak labor law enforcement, limited union organization, high levels of informality, historically marginalized populations excluded from workforce and educational opportunities and a population more vulnerable to the risks of labor exploitation, child labor, the antibiotics and natural disasters.

ILAB seeks to strengthen global labor standards, enforce trading partnersâ labor commitments, promote racial and gender equity, and combat child labor how fast does zithromax work abuses, forced labor and human trafficking. Learn more about the funding opportunity.HIGH POINT, NC â The U.S. Department of Labor and how fast does zithromax work Fastenal Co.

Have agreed to resolve alleged systemic gender-based hiring discrimination that affected 483 female job applicants at its High Point facility from Dec. 7, 2016 through how fast does zithromax work July 31, 2018. A routine compliance investigation by the departmentâs Office of Federal Contract Compliance Programs found the industrial and construction supply distributor violated Executive Order 11246 in its hiring of laborer and helper positions.

ÂFederal contractors must ensure that their employment practices do not discriminate on the basis of race, color, religion, sex, sexual how fast does zithromax work orientation, gender identity or national origin,â said Office of Federal Contract Compliance Programs Southeast Regional Director Aida Collins in Atlanta. ÂBy reaching this agreement with the U.S. Department of how fast does zithromax work Labor, Fastenal Co.

Has demonstrated it is committed to resolving the issues raised and ensuring that measures are in place to provide equal employment opportunities.â Based in Winona, Minnesota, Fastenal Co. Sells and distributes fasteners, tools, safety equipment and janitorial supplies primarily in North America, and in Asia, Europe, and Central and South America. It also how fast does zithromax work has 14 regional distribution centers.

The Office of Federal Contract Compliance Programs enforces Executive Order 11246, Section 503 of the Rehabilitation Act of 1973 and the Vietnam Era Veteransâ Readjustment Assistance Act of 1974. For more information, call the Office of Federal Contract Compliance Programs how fast does zithromax work toll-free helpline at 800-397-6251. Learn more about OFCCP.

If you think you may be how fast does zithromax work a class member employed by Fastenal Co., use OFCCPâs Class Member Locator to learn more about this and other settlements. Learn more about OFCCP, or call 800-397-6251. OFCCP recovered over $116 million for more than 138,000 employees and job seekers who were discriminated against in compliance reviews from October 2016-September 2020..

WASHINGTON, DC â The zithromax discount card U.S. Department of Labor today announced its intent to award up to $20 million in grant funding to elevate workersâ rights and improve working conditions in the Central American countries of El Salvador, Guatemala and Honduras. Administered by the Bureau of International Labor Affairs, these funding opportunities will finance projects to promote respect for labor rights and labor rights compliance in the region that are zithromax discount card aligned with the Biden-Harris administrationâs Root Causes of Migration Strategy. The $20 million in available funding includes up to $7 million to address child labor, forced labor and other unacceptable conditions of work among El Salvador, Guatemala and Hondurasâ vulnerable populations, including indigenous communities and people of African descent. The department published a funding opportunity announcement yesterday that will fund this project to improve the ability of zithromax discount card communities to come together and collaborate with governments, the private sector and others to address unacceptable work conditions.

In the coming weeks, the department will announce an additional $13 million in funding opportunities aimed at improving occupational safety and health conditions, access to social protection services and respect for workersâ rights in Central America. The administrationâs Root Causes strategy recognizes that decent work and the promotion of labor rights fosters zithromax discount card inclusive economic growth. Through ILAB, the department will use its mandate to address issues related to labor rights compliance in the region and engage labor, worker organizations, womenâs empowerment organizations and other organizations in the U.S., El Salvador, Guatemala and Honduras to inform future programming. The regionâs challenges include weak labor law enforcement, limited union organization, high levels of informality, historically marginalized populations excluded from workforce and educational opportunities and a population more vulnerable to the risks of labor exploitation, child labor, the antibiotics and natural disasters. ILAB seeks to strengthen global labor standards, enforce trading partnersâ labor commitments, promote zithromax discount card racial and gender equity, and combat child labor abuses, forced labor and human trafficking.

Learn more about the funding opportunity.HIGH POINT, NC â The U.S. Department of Labor zithromax discount card and Fastenal Co. Have agreed to resolve alleged systemic gender-based hiring discrimination that affected 483 female job applicants at its High Point facility from Dec. 7, 2016 through July 31, 2018 zithromax discount card. A routine compliance investigation by the departmentâs Office of Federal Contract Compliance Programs found the industrial and construction supply distributor violated Executive Order 11246 in its hiring of laborer and helper positions.

Fastenal provides services under contract to the Department of the Air Force. Fastenal will pay $168,000 in back wages and interest to the affected applicants and make 24 job offers, as positions become zithromax discount card available. In its conciliation agreement, the company has also agreed to ensure that its selection process, personnel practices and hiring policies are free from discrimination, and its recordkeeping methods meet legal requirements. ÂFederal contractors must ensure that their employment practices do not discriminate on zithromax discount card the basis of race, color, religion, sex, sexual orientation, gender identity or national origin,â said Office of Federal Contract Compliance Programs Southeast Regional Director Aida Collins in Atlanta. ÂBy reaching this agreement with the U.S.

Department of zithromax discount card Labor, Fastenal Co. Has demonstrated it is committed to resolving the issues raised and ensuring that measures are in place to provide equal employment opportunities.â Based in Winona, Minnesota, Fastenal Co. Sells and distributes fasteners, tools, safety equipment and janitorial supplies primarily in North America, and in Asia, Europe, and Central and South America. It also has 14 regional distribution centers zithromax discount card. The Office of Federal Contract Compliance Programs enforces Executive Order 11246, Section 503 of the Rehabilitation Act of 1973 and the Vietnam Era Veteransâ Readjustment Assistance Act of 1974.

For more information, call the zithromax discount card Office of Federal Contract Compliance Programs toll-free helpline at 800-397-6251. Learn more about OFCCP. If you think zithromax discount card you may be a class member employed by Fastenal Co., use OFCCPâs Class Member Locator to learn more about this and other settlements. Learn more about OFCCP, or call 800-397-6251. OFCCP recovered over $116 million for more than 138,000 employees and job seekers who were discriminated against in compliance reviews from October 2016-September 2020..

Zithromax equivalent

On this page IntroductionEach year, Health Canada receives thousands of reports of suspected zithromax equivalent adverse reactions (side effects) about drugs and natural health products and of suspected medical device incidents. These reports, captured through the Canada Vigilance Program, contribute to Health Canadaâs post-market monitoring of health product safety.Manufacturers, importers, hospitals and other mandatory reporters are required to report to Health Canada on adverse reactions and incidents related to marketed health products. Health Canada also encourages health care professionals, patients, caregivers and zithromax equivalent consumers to submit voluntary reports about serious adverse reactions or incidents concerning drugs, natural health products or medical devices.

Data from both the Canada Vigilance Program and other sources, like recalls that are reported to Health Canada, provide critical information that helps improve patient safety.Building the Canada Vigilance Program Since the Canada Vigilance Program began, the number of reports submitted to Health Canada has increased every year. This increase is due to a number of factors, such as. The rise in the overall number of marketed health products the implementation of mandatory reporting for all hospitals in Canada the expansion of the Canadian Medical Devices Sentinel Network (CMDSNet), Health Canadaâs proactive surveillance program that encourages program participants to report medical device incidents the implementation of voluntary consumer reporting Health Canadaâs efforts to promote simpler and easier ways to report a changing and aging Canadian population with changing health needs an increase in patient safety programs by industry, which leads to an increase in targeted detection and reporting proactive information gathering efforts by Health Canada, which lead to the discovery of unreported adverse drug reactions and medical device incidents While the number of reports is increasing, we know that adverse zithromax equivalent drug reactions and medical device incidents continue to be under-reported in Canada and worldwide.Improving the Canada Vigilance ProgramHealth Canada continues to improve the quantity and quality of all incoming Canada Vigilance Program data by.

Providing feedback to stakeholders on the quality of reports identifying and flagging duplicate reports in the Canada Vigilance database cleaning the data so it can be analyzed using automated data entry to reduce human error implementing mandatory reporting by hospitals of serious adverse drug reactions and medical device incidents (as of December 2019) About the 2019 dataThis page summarizes data on adverse reaction reports received by Health Canada during 2019 and key trends over the past 10 years. We present data on. Adverse reactions to drugs and natural health products incidents related to the use of zithromax equivalent medical devices recalls that occurred after products were approved for sale in CanadaData on adverse drug reactions and medical device incidents are based on reports sent to Health Canada through the Canada Vigilance Program.

Recall data are based on the work of the Regulatory Operations and Enforcement Branch. The statistics on this page are based only on Canadian reports and do not include data from other countries (foreign reports).Adverse reactions to drugs and natural health productsTotal number of reportsIn 2019, Health Canada received 96,559 domestic reports.Over the last 10 years. The number of Canadian reports has increased over 4-fold (from 22,211 reports in 2010 to zithromax equivalent 96,559 reports in 2019) Health Canada received an average of 8,000 Canadian reports per month in 2019 Source of reportsIn 2019.

90,350 (93.6%) of reports came from mandatory reporters Canada has a strong reporting system in place to ensure that industry is responsible for their products and that they submit reports in a timely manner 3,849 (4.0%) were voluntary reports from health professionals working outside of hospitals 956 (1.0%) were voluntary reports from the general population 1,248 (1.3%) were from hospitals, which, until December 16, 2019, submitted reports to Health Canada on a voluntary basis Going forward, Health Canada anticipates receiving a larger volume of reports from hospitals because of the new mandatory reporting regulations Over the last 10 years. 9 out of 10 reports received at Health Canada were submitted by industryTypes of reported productsOne or more drugs or natural health products may be mentioned in a report because the reporter suspects they played a role in the adverse reaction.In 2019. A total of 208,383 drugs or natural health products were mentioned in the 96,559 reports sent to Health Canada pharmaceutical drug products were most often reported, at 68.1% zithromax equivalent biotechnological products were the second most frequently reported, at 28.1% within these product categories, the specific products most often reported were.

immunosuppressants (drugs that aim to reduce the activity of the bodyâs immune system) at 32.5% of all reported suspected products anti-neoplastic agents (drugs used to treat cancer) at 16.4% of all reported suspected products Over the last 10 years. The most common products reported each year in adverse drug reactions have been immunosuppressants and anti-neoplastic agents these numbers reflect the. large number of anti-neoplastic agents approved for use in Canada known risks associated with these products large number of patient reporting programs in place for these products severity of the underlying disease in the population being treated each year, more drugs and natural health products are included in the adverse reactions reported to Health Canada from 25,668 zithromax equivalent reported products in 2010 to 208,383 reported products in 2019, an 8-fold increase this may be due to improved reporting mechanisms and increased general awareness of the risks involved in using multiple products with the reporting of more drugs and natural health products, we can look at product interactions seen in real-world situations involving Canadians with complex medical needs Adverse reactionsA report may mention more than one adverse reaction.

In 2019. 420,120 adverse reactions were mentioned in the reports sent to Health Canada the top 4 reported adverse reactions included. general disorders and administration site conditions, such as pain or weakness (96,640, or 23.0%) gastrointestinal disorders, such as vomiting or diarrhea (37,892, or 9.0%) investigations that include performing tests and physical examinations (33,651, or 8.0%) musculoskeletal zithromax equivalent and connective tissue disorders resulting in swelling or joint pain (33,531, or 8.0%) Over the last 10 years.

Each year, more adverse reactions are included in the reports sent to Health Canada from 79,249 adverse reactions in 2010 to 420,120 reported reactions in 2019, a 5-fold increase this may be due to improved reporting mechanisms if more reporters report similar details about adverse reactions, this will help to reinforce ongoing issues seen with certain products this may signal a potential public health issue for further review OutcomesIn 2019. 7 out of 10 (67,754, or 70.2%) adverse reactions reported to Health Canada were of a serious natureOver the last 10 years. The majority of adverse reaction reports were serious because zithromax equivalent.

regulated parties are legally obligated to report all serious reactions to Health Canada health professionals and consumers are more likely to report serious reactions that result in harm We make it a priority to review the most serious product safety issues affecting Canadians. However, all reports are important. Together, they zithromax equivalent help to flag potential product safety issues .In 2019.

6,119 (6.3%) reports mentioned a suspected link between a death that had occurred and the use of a drug or natural health product 18,852 (19.5%) reports mentioned hospitalization 2,483 (2.6%) reports mentioned the occurrence of a potentially life-threatening condition 193 (0.2%) reports mentioned a congenital anomaly (birth defect) 52,119 (54.0%) reports indicated that, without intervention, the reported adverse reaction could have resulted in a serious outcomeOutcomes are complex and may be the result of multiple factors, including existing medical conditions or the progression of an illness. A reported outcome may not be directly caused by the use of a drug or natural health product. Increasing the quantity and quality of reports submitted to zithromax equivalent Health Canada can provide more robust evidence and help to determine if there is a link to specific products.

22,809 (92.2%) incidents were reported by industry Canada has a strong reporting system in place where industry is held accountable for their products and must report incidents in a timely manner to Health Canada as per the Medical Devices Regulations 1,018 (4.1%) incidents were based on voluntary reports from the community Voluntary reports from consumers, health care professionals and others add to the quality and quantity of incoming data and help provide a comprehensive picture of medical device problems or issues 554 (2.2%) incidents were reported by health care institutions participating in CMDSNet CMDSNet is a proactive surveillance program that encourages the reporting of medical device problem reports from participating institutions CMDSNet provides a complementary data source for post-market safety evaluations Over the last 10 years. 9 out of 10 incidents were zithromax equivalent reported by industryWith the introduction of mandatory reporting for all hospitals in December 2019, we anticipate receiving a larger volume of incident reports from hospitals in the future.Types of reported productsA medical device incident may involve more than one medical device. This means that multiple devices may be described in the reports sent to Health Canada.In 2019.

A total of 25,519 suspected medical devices were mentioned in the incidents reported to Health Canada the most frequently reported devices were used in. general and zithromax equivalent plastic surgery (8,926, or 35.8%) general hospital settings (5,977, or 24.0%) cardiovascular care, like pacemakers, defibrillators and stents (2,478, or 10.0%) Over the last 10 years prior to 2019. Devices for general hospital use (such as needles, catheters and syringes) were most often reported these incidents do not mean that these devices have more risk or cause more harm.

Rather, they were. reported more frequently to Health zithromax equivalent Canada used more often more readily available when compared to other medical devices in more specialized categories In 2019. The category of general and plastic surgery (with devices such as electrodes, implants and surgical staplers) was the most reported this was due to the submission of a large number of reports related to breast implants this prompted Health Canada and its partners to.

investigate the risks associated with some types of breast implants take some unsafe breast implant products off the market educate Canadians about breast implants Over the last 10 years. Each year, more suspected products zithromax equivalent are being reported in the medical device incidents sent to Health Canada from 6,544 devices in 2010 to 25,519 devices in 2019, a 4-fold increase this may be due to improved reporting mechanisms and increased general awareness of the importance of reporting increased reporting gives us the ability to better understand what happens when people use more than one device at a time Device issuesMore than one issue or problem with a device may be mentioned in a medical device incident. In 2019.

28,124 issues related to the use of medical devices were experienced material integrity problems (for example, material rupture, a burst container or vessel, or breaking) were mentioned 28.1% of the time mechanical problems (especially fluid leaks) were mentioned 21.1% of the time Over the last 10 years. The types of reported issues may vary from year to year more issues with medical devices are being included in the reports sent to Health Canada from 374 issues in 2010 to 28,124 issues in 2019 this is likely due to improved reporting practices, which are capturing more detail, and the increase in the number of incoming reports we are zithromax equivalent working on improving standardized reporting and categorization of information, which will increase the quality and usability of the dataHealth effectsMore than one health effect may be mentioned in a medical device incident.In 2019. 22,518 health effects were mentioned in incidents reported to Health Canada the top reported health effect was hyperglycemia (high blood sugar), which was reported in 1,896 (8.4%) incidents other reported health effects included.

capsular contracture (when the capsule surrounding an implanted device distorts) (1,671, or 7.4%) injury (1,338, or 5.9%) pain (761, or 3.4%) Over the last 10 years. Hyperglycemia has remained a top reported health effect this is not zithromax equivalent unexpected. Devices that measure blood sugar, such as glucose meters and glucose monitoring systems, are some of the most frequently used medical devices in CanadaOutcomesIn 2019.

7,949 (34.5%) medical device incidents reported to Health Canada were of a serious natureOver the last 10 years. The proportion of medical device incidents zithromax equivalent that were serious. varied between 10.3% and 19.6% from 2010 to 2018 jumped to over one-third of all incidents in 2019 this was due to the submission of a large number of reports related to breast implants While priority is given to reports that are flagged as serious, all reports are important.

Taken together, reports of medical device incidents may indicate a potential public health issue. In 2019 zithromax equivalent. 85 (0.4%) of all medical device incidents mentioned a possible link between a death that occurred and the use of a medical device however, the reported death may not have been directly caused by the suspected medical device incident surgery was the most common outcome reported in medical device incidents, with 3,365 incidents involving some form of surgery 1,659 (49.3%) were revision surgeries (to fix an issue) 1,291 (38.4%) were explantations (removal of device) 1,274 (76.8%) of the reported revision surgeries and 1,079 (83.6%) of the explantations involved breast implants 3,791 (19.7%) incidents indicated that there was no reported patient involvement or consequences to a patient these incidents did not cause harm, but were reported to Health Canada because they were near misses under different circumstances or without intervention, serious harm may have occurred this information helps us work with industry to take action before an actual harm occurs Marketed health product recallsRecallsA drug or natural health product recall results in the correction of a distributed product or its removal from further sale or use.A medical device recall may result in.

Removal of a product from further sale or use an on-site correction of the device an advisement to consumers of problems or potential problems with their device alternative labelling, which may include updates to instructions or manualsIn 2019, Health Canada received reports of. 162 pharmaceutical drug recalls 32 natural health product recalls 822 medical device recallsFor each report, the Department evaluates the recall strategy to ensure the appropriate corrective actions are taken and zithromax equivalent that the actions are effective. Identified health risksThere are 3 types of health hazards.

Type I. Using or being exposed to a product will probably cause serious adverse health zithromax equivalent effects or death Type II. Using or being exposed to a product may cause temporary adverse health consequences or the possibility of serious adverse health effects is remote Type III.

Using or being exposed to a product is not likely to cause any adverse health effectsOf the 162 recalls of pharmaceutical drugs (prescription, non-prescription, radiopharmaceutical and active pharmaceutical ingredient). 52 were classified as type I 59 were classified as type II 51 were classified as type IIIOf the zithromax equivalent 32 natural health product recalls. 16 were classified as type I 8 were classified as type II 8 were classified as type IIIOf the 822 medical device recalls.

37 were classified as type I 493 were classified as type II 292 were classified as type IIIRelated links.

On this page IntroductionEach year, Health Canada receives thousands of reports of suspected adverse reactions (side effects) about drugs and natural health products and of suspected medical device zithromax discount card incidents. These reports, captured through the Canada Vigilance Program, contribute to Health Canadaâs post-market monitoring of health product safety.Manufacturers, importers, hospitals and other mandatory reporters are required to report to Health Canada on adverse reactions and incidents related to marketed health products. Health Canada also encourages health care professionals, patients, caregivers and consumers to submit voluntary reports about serious adverse reactions or incidents concerning drugs, natural zithromax discount card health products or medical devices. Data from both the Canada Vigilance Program and other sources, like recalls that are reported to Health Canada, provide critical information that helps improve patient safety.Building the Canada Vigilance Program Since the Canada Vigilance Program began, the number of reports submitted to Health Canada has increased every year. This increase is due to a number of factors, such as.

The rise in the overall number of marketed health products the implementation of mandatory reporting for all hospitals in Canada the expansion of the Canadian Medical Devices Sentinel Network (CMDSNet), Health Canadaâs proactive surveillance program that encourages program participants to report medical device incidents the implementation of voluntary consumer reporting Health Canadaâs efforts to promote simpler and easier ways to report a changing and aging Canadian population with changing health needs an increase in patient safety programs by industry, which leads to an increase in targeted detection and reporting proactive information gathering efforts by Health Canada, which lead to the discovery of unreported adverse drug reactions and medical device incidents While the number of reports is increasing, we know that adverse drug reactions and medical device incidents continue to be under-reported in Canada and worldwide.Improving the Canada Vigilance ProgramHealth Canada continues to zithromax discount card improve the quantity and quality of all incoming Canada Vigilance Program data by. Providing feedback to stakeholders on the quality of reports identifying and flagging duplicate reports in the Canada Vigilance database cleaning the data so it can be analyzed using automated data entry to reduce human error implementing mandatory reporting by hospitals of serious adverse drug reactions and medical device incidents (as of December 2019) About the 2019 dataThis page summarizes data on adverse reaction reports received by Health Canada during 2019 and key trends over the past 10 years. We present data on. Adverse reactions to drugs and natural health products incidents related to the use of medical devices recalls that occurred after products were approved for sale in CanadaData on adverse zithromax discount card drug reactions and medical device incidents are based on reports sent to Health Canada through the Canada Vigilance Program. Recall data are based on the work of the Regulatory Operations and Enforcement Branch.

The statistics on this page are based only on Canadian reports and do not include data from other countries (foreign reports).Adverse reactions to drugs and natural health productsTotal number of reportsIn 2019, Health Canada received 96,559 domestic reports.Over the last 10 years. The number of Canadian reports has increased over 4-fold (from 22,211 reports in 2010 to 96,559 reports in 2019) Health Canada zithromax discount card received an average of 8,000 Canadian reports per month in 2019 Source of reportsIn 2019. 90,350 (93.6%) of reports came from mandatory reporters Canada has a strong reporting system in place to ensure that industry is responsible for their products and that they submit reports in a timely manner 3,849 (4.0%) were voluntary reports from health professionals working outside of hospitals 956 (1.0%) were voluntary reports from the general population 1,248 (1.3%) were from hospitals, which, until December 16, 2019, submitted reports to Health Canada on a voluntary basis Going forward, Health Canada anticipates receiving a larger volume of reports from hospitals because of the new mandatory reporting regulations Over the last 10 years. 9 out of 10 reports received at Health Canada were submitted by industryTypes of reported productsOne or more drugs or natural health products may be mentioned in a report because the reporter suspects they played a role in the adverse reaction.In 2019. A total of 208,383 zithromax discount card drugs or natural health products were mentioned in the 96,559 reports sent to Health Canada pharmaceutical drug products were most often reported, at 68.1% biotechnological products were the second most frequently reported, at 28.1% within these product categories, the specific products most often reported were.

immunosuppressants (drugs that aim to reduce the activity of the bodyâs immune system) at 32.5% of all reported suspected products anti-neoplastic agents (drugs used to treat cancer) at 16.4% of all reported suspected products Over the last 10 years. The most common products reported each year in adverse drug reactions have been immunosuppressants and anti-neoplastic agents these numbers reflect the. large number of anti-neoplastic agents approved for use in Canada known risks associated with these products large number of patient reporting programs in place for these products severity of the underlying disease in the population being treated each year, more drugs zithromax discount card and natural health products are included in the adverse reactions reported to Health Canada from 25,668 reported products in 2010 to 208,383 reported products in 2019, an 8-fold increase this may be due to improved reporting mechanisms and increased general awareness of the risks involved in using multiple products with the reporting of more drugs and natural health products, we can look at product interactions seen in real-world situations involving Canadians with complex medical needs Adverse reactionsA report may mention more than one adverse reaction. In 2019. 420,120 adverse reactions were mentioned in the reports sent to Health Canada the top 4 reported adverse reactions included.

general disorders and administration site conditions, such as pain or weakness (96,640, or zithromax discount card 23.0%) gastrointestinal disorders, such as vomiting or diarrhea (37,892, or 9.0%) investigations that include performing tests and physical examinations (33,651, or 8.0%) musculoskeletal and connective tissue disorders resulting in swelling or joint pain (33,531, or 8.0%) Over the last 10 years. Each year, more adverse reactions are included in the reports sent to Health Canada from 79,249 adverse reactions in 2010 to 420,120 reported reactions in 2019, a 5-fold increase this may be due to improved reporting mechanisms if more reporters report similar details about adverse reactions, this will help to reinforce ongoing issues seen with certain products this may signal a potential public health issue for further review OutcomesIn 2019. 7 out of 10 (67,754, or 70.2%) adverse reactions reported to Health Canada were of a serious natureOver the last 10 years. The majority of adverse reaction zithromax discount card reports were serious because. regulated parties are legally obligated to report all serious reactions to Health Canada health professionals and consumers are more likely to report serious reactions that result in harm We make it a priority to review the most serious product safety issues affecting Canadians.

However, all reports are important. Together, they help to flag potential product safety issues zithromax discount card .In 2019. 6,119 (6.3%) reports mentioned a suspected link between a death that had occurred and the use of a drug or natural health product 18,852 (19.5%) reports mentioned hospitalization 2,483 (2.6%) reports mentioned the occurrence of a potentially life-threatening condition 193 (0.2%) reports mentioned a congenital anomaly (birth defect) 52,119 (54.0%) reports indicated that, without intervention, the reported adverse reaction could have resulted in a serious outcomeOutcomes are complex and may be the result of multiple factors, including existing medical conditions or the progression of an illness. A reported outcome may not be directly caused by the use of a drug or natural health product. Increasing the quantity zithromax discount card and quality of reports submitted to Health Canada can provide more robust evidence and help to determine if there is a link to specific products.

This in turn can keep Canadians safer from the harmful effects of certain health products. Medical device incidentsTotal number of incidentsIn 2019, Health Canada received information about 25,235 domestic incidents.Over the last 10 years. The number of Canadian incidents has increased almost 4-fold (from 6,326 incidents in 2010 to 24,726 incidents in zithromax discount card 2019) an average of 2,000 Canadian incidents were reported each month in 2019Source of reportsIn 2019. 22,809 (92.2%) incidents were reported by industry Canada has a strong reporting system in place where industry is held accountable for their products and must report incidents in a timely manner to Health Canada as per the Medical Devices Regulations 1,018 (4.1%) incidents were based on voluntary reports from the community Voluntary reports from consumers, health care professionals and others add to the quality and quantity of incoming data and help provide a comprehensive picture of medical device problems or issues 554 (2.2%) incidents were reported by health care institutions participating in CMDSNet CMDSNet is a proactive surveillance program that encourages the reporting of medical device problem reports from participating institutions CMDSNet provides a complementary data source for post-market safety evaluations Over the last 10 years. 9 out of zithromax discount card 10 incidents were reported by industryWith the introduction of mandatory reporting for all hospitals in December 2019, we anticipate receiving a larger volume of incident reports from hospitals in the future.Types of reported productsA medical device incident may involve more than one medical device.

This means that multiple devices may be described in the reports sent to Health Canada.In 2019. A total of 25,519 suspected medical devices were mentioned in the incidents reported to Health Canada the most frequently reported devices were used in. general and plastic surgery (8,926, or 35.8%) general hospital settings (5,977, or zithromax discount card 24.0%) cardiovascular care, like pacemakers, defibrillators and stents (2,478, or 10.0%) Over the last 10 years prior to 2019. Devices for general hospital use (such as needles, catheters and syringes) were most often reported these incidents do not mean that these devices have more risk or cause more harm. Rather, they were.

reported more frequently to Health Canada used more often more readily available when compared to other medical devices in more specialized categories In 2019 zithromax discount card. The category of general and plastic surgery (with devices such as electrodes, implants and surgical staplers) was the most reported this was due to the submission of a large number of reports related to breast implants this prompted Health Canada and its partners to. investigate the risks associated with some types of breast implants take some unsafe breast implant products off the market educate Canadians about breast implants Over the last 10 years. Each year, more suspected products are being reported in the medical device incidents sent to Health Canada from 6,544 devices in 2010 to 25,519 devices in 2019, a 4-fold increase this may be due to improved reporting mechanisms and increased general awareness of the importance zithromax discount card of reporting increased reporting gives us the ability to better understand what happens when people use more than one device at a time Device issuesMore than one issue or problem with a device may be mentioned in a medical device incident. In 2019.

28,124 issues related to the use of medical devices were experienced material integrity problems (for example, material rupture, a burst container or vessel, or breaking) were mentioned 28.1% of the time mechanical problems (especially fluid leaks) were mentioned 21.1% of the time Over the last 10 years. The types of reported issues may vary from year to year more issues with medical devices are being included in the reports sent to Health Canada from 374 issues in 2010 to 28,124 issues in 2019 this is likely due zithromax discount card to improved reporting practices, which are capturing more detail, and the increase in the number of incoming reports we are working on improving standardized reporting and categorization of information, which will increase the quality and usability of the dataHealth effectsMore than one health effect may be mentioned in a medical device incident.In 2019. 22,518 health effects were mentioned in incidents reported to Health Canada the top reported health effect was hyperglycemia (high blood sugar), which was reported in 1,896 (8.4%) incidents other reported health effects included. capsular contracture (when the capsule surrounding an implanted device distorts) (1,671, or 7.4%) injury (1,338, or 5.9%) pain (761, or 3.4%) Over the last 10 years. Hyperglycemia has zithromax discount card remained a top reported health effect this is not unexpected.

Devices that measure blood sugar, such as glucose meters and glucose monitoring systems, are some of the most frequently used medical devices in CanadaOutcomesIn 2019. 7,949 (34.5%) medical device incidents reported to Health Canada were of a serious natureOver the last 10 years. The proportion of medical device incidents that were serious zithromax discount card. varied between 10.3% and 19.6% from 2010 to 2018 jumped to over one-third of all incidents in 2019 this was due to the submission of a large number of reports related to breast implants While priority is given to reports that are flagged as serious, all reports are important. Taken together, reports of medical device incidents may indicate a potential public health issue.

In 2019 zithromax discount card. 85 (0.4%) of all medical device incidents mentioned a possible link between a death that occurred and the use of a medical device however, the reported death may not have been directly caused by the suspected medical device incident surgery was the most common outcome reported in medical device incidents, with 3,365 incidents involving some form of surgery 1,659 (49.3%) were revision surgeries (to fix an issue) 1,291 (38.4%) were explantations (removal of device) 1,274 (76.8%) of the reported revision surgeries and 1,079 (83.6%) of the explantations involved breast implants 3,791 (19.7%) incidents indicated that there was no reported patient involvement or consequences to a patient these incidents did not cause harm, but were reported to Health Canada because they were near misses under different circumstances or without intervention, serious harm may have occurred this information helps us work with industry to take action before an actual harm occurs Marketed health product recallsRecallsA drug or natural health product recall results in the correction of a distributed product or its removal from further sale or use.A medical device recall may result in. Removal of a product from further sale or use an on-site correction of the device an advisement to consumers of problems or potential problems with their device alternative labelling, which may include updates to instructions or manualsIn 2019, Health Canada received reports of. 162 pharmaceutical drug recalls 32 natural health product recalls 822 medical device recallsFor each report, the Department zithromax discount card evaluates the recall strategy to ensure the appropriate corrective actions are taken and that the actions are effective. Identified health risksThere are 3 types of health hazards.

Type I. Using or being exposed to a product will probably cause serious adverse health effects zithromax discount card or death Type II. Using or being exposed to a product may cause temporary adverse health consequences or the possibility of serious adverse health effects is remote Type III. Using or being exposed to a product is not likely to cause any adverse health effectsOf the 162 recalls of pharmaceutical drugs (prescription, non-prescription, radiopharmaceutical and active pharmaceutical ingredient). 52 were classified as type I 59 were classified as type II 51 were classified as type IIIOf the 32 natural health product recalls.

16 were classified as type I 8 were classified as type II 8 were classified as type IIIOf the 822 medical device recalls. 37 were classified as type I 493 were classified as type II 292 were classified as type IIIRelated links.

Zithromax discount card

Zithromax for urinary tract infection

Zithromax for urinary tract infection

Zithromax discount card

Zithromax discount card

Zithromax discount card

Zithromax discount card

Zithromax discount card

Zithromax discount card